SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



SCHEDULE 13E-3
RULE 13E-3 TRANSACTION STATEMENT
UNDER SECTION 13(E) OF
THE SECURITIES EXCHANGE ACT OF 1934



AGROFRESH SOLUTIONS, INC.
(Name of the Issuer)



AgroFresh Solutions, Inc.
Project Cloud Merger Sub, Inc.
Project Cloud Holdings, LLC
Paine Schwartz Food Chain Fund V, L.P.
Paine Schwartz Food Chain Fund V GP, L.P.
Paine Schwartz Food Chain Fund V GP, Ltd.
Paine Schwartz Food Chain Fund VI, L.P.
PSP AGFS Holdings, L.P.
Paine Schwartz Partners, LLC
(Names of Persons Filing Statement)

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

00856G109
(CUSIP Number of Class of Securities)



 AgroFresh Solutions, Inc.
One Washington Square
510-530 Walnut Street, Suite 1350
Philadelphia, PA 19106
(267) 317-9139
Attn: Thomas Ermi
Project Cloud Merger Sub, Inc.
Project Cloud Holdings, LLC
Paine Schwartz Food Chain Fund V, L.P.
Paine Schwartz Food Chain Fund V GP, L.P.
Paine Schwartz Food Chain Fund V GP, Ltd.
Paine Schwartz Food Chain Fund VI, L.P.
PSP AGFS Holdings, L.P.
Paine Schwartz Partners, LLC
c/o Paine Schwartz Partners, LLC
475 Fifth Avenue, 17th Floor
New York, NY 10017
(212) 379-7200
Attn: Kevin Schwartz & Alexander Corbacho

(Name, Address, and Telephone Numbers of Person Authorized to Receive Notices
and Communications on Behalf of the Persons Filing Statement)

With copies to

Morrison & Foerster LLP
250 West 55th Street
New York, NY 10019
(212) 468-8000
Attn: Mitchell S. Presser & Omar E. Pringle
 
Kirkland & Ellis LLP
300 N. LaSalle Street
Chicago, IL 60654
(312) 862-2000
Attn: Corey D. Fox, P.C. & Peter Stach
Morris, Nichols, Arsht & Tunnell LLP
1201 N. Market Street
Wilmington, DE 19801
(302) 351-9169
Attn: Eric Klinger-Wilensky
 



This statement is filed in connection with (check the appropriate box):

a.
The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.
b.
The filing of a registration statement under the Securities Act of 1933.
c.
A tender offer.
d.
None of the above.

Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☒

Check the following box if the filing is a final amendment reporting the results of the transaction: ☐

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction or passed upon the adequacy or accuracy of the disclosure in this transaction statement on Schedule 13E-3. Any representation to the contrary is a criminal offense.


Introduction

This Transaction Statement on Schedule 13E-3 (“Transaction Statement”) is being filed with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), by (1) AgroFresh Solutions, Inc. (“AgroFresh” or the “Company”); (2) Project Cloud Holdings, LLC, a Delaware limited liability company (“Parent”), (3) Project Cloud Merger Sub, Inc. (“Merger Sub”), a Delaware corporation, (4) Paine Schwartz Food Chain Fund V, L.P. (“PSV LP”), a Cayman Islands exempted limited partnership, (5) Paine Schwartz Food Chain Fund V GP, L.P. (“PSV GP LP”), a Cayman Islands exempted limited partnership, (6) Paine Schwartz Food Chain Fund V GP, Ltd (“PSV GP LTD”), a Cayman Islands exempted limited partnership, (7) Paine Schwartz Food Chain Fund VI, L.P. (“Sponsor”), a Cayman Islands exempted limited partnership, (8) PSP AGFS Holdings, L.P. (“PSP AGFS”), a Delaware limited partnership and (9) Paine Schwartz Partners, LLC (“PSP”), a Delaware limited liability company (each of (1) through (9) a “Filing Person,” and collectively, the “Filing Persons”). Parent and Merger Sub are affiliates of PSP AGFS, an investment fund managed by PSP that holds approximately 39% of the voting power of the issued and outstanding shares of the Company’s capital stock.

This Transaction Statement relates to the Agreement and Plan of Merger, dated as of November 21, 2022 (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, Parent and Merger Sub.

If the Merger Agreement is adopted by the Company’s stockholders and the other conditions under the Merger Agreement are either satisfied or waived, Merger Sub will be merged with and into the Company (which we refer to as the “Merger”), the separate corporate existence of Merger Sub will cease and the Company will continue its corporate existence under Delaware law as the surviving corporation in the Merger (the “Surviving Corporation”) and as a subsidiary of Parent. Upon completion of the Merger, each share of the Company’s common stock, par value $0.0001 per share (“Company common stock”) issued and outstanding immediately prior to the effective time of the Merger (other than (1) shares of Company common stock owned by the Company and not held on behalf of third parties, (2) shares of Company common stock owned by Parent or Merger Sub and (3) shares of Company common stock that are owned by stockholders of the Company who did not vote in favor of the Merger Agreement or the Merger and who have perfected and not withdrawn a demand for appraisal rights with respect to such shares pursuant to Section 262 of the General Corporation Law of the State of Delaware) will be automatically converted into the right to receive $3.00 in cash per share, without interest (the “Merger Consideration”). Following the completion of the Merger, the shares of Company common stock will no longer be publicly traded, and holders of such shares of Company common stock that have been converted into the right to receive the Merger Consideration will cease to have any ownership interest in the Company.

Concurrently with the filing of this Transaction Statement, the Company is filing with the SEC a proxy statement (the “Proxy Statement”) under Regulation 14A of the Exchange Act, pursuant to which the Company’s board of directors (the “Board”) is soliciting proxies from stockholders of the Company in connection with the Merger. The Proxy Statement is attached hereto as Exhibit (a)(1). A copy of the Merger Agreement is attached to the Proxy Statement as Annex A and is incorporated herein by reference. As of the date hereof, the Proxy Statement is in preliminary form, and is subject to completion or amendment. Terms used but not defined in this Transaction Statement have the meanings assigned to them in the Proxy Statement. A copy of the Proxy Statement is attached hereto as Exhibit (a)(1).

A special committee (the “Special Committee”) of the Board, consisting solely of non-management independent directors of the Company who are independent of, and not affiliated with, PSP or its affiliates, acting in reliance in part upon the advice of independent legal and financial advisors, unanimously (1) determined that the terms of the Merger Agreement and the transactions contemplated thereby, including the Merger are (i) advisable, fair to, and in the best interests of the “Unaffiliated Stockholders” of the Company, defined to mean holders of shares of Company common stock other than Paine Schwartz Food Chain Fund VI, L.P., PSP AGFS Holdings, L.P. and their respective affiliates (including Parent and Merger Sub), the members of the Board, any person that the Company has determined to be an “officer” of the Company within the meaning of Rule 16a-1(f) of the Exchange Act, or any of their respective “associates” or members of their “immediate family” (as such terms are defined in Rules 12b-2 and 16a-1 of the Exchange Act), and (ii) substantively and procedurally fair to the unaffiliated security holders (as defined in Rule 13e-3 of the Exchange Act), (2) determined that it is in the best interests of the Unaffiliated Stockholders and declared it advisable to enter into the Merger Agreement and (3) recommended that the Board approve and authorize the Merger Agreement, the equity commitment letter, dated as of November 21, 2022, by and between Parent and the Sponsor, the voting and support agreement, dated as of November 21, 2022, by and among Company and affiliates of Parent, including PSP, and the Merger and recommend that the stockholders of the Company vote to adopt and approve the Merger Agreement.

The Board (other than John Atkin, Alexander Corbacho, Kevin Schwartz, and Kay Kuenker, who recused themselves due to their affiliation with, or designation to the Board by, PSP), acting in accordance with the recommendation of the Special Committee, unanimously (1) determined that the terms of the Merger Agreement and the transactions contemplated thereby, including the Merger, are fair to, and in the best interests of, the Company’s stockholders, including the Unaffiliated Stockholders and substantively and procedurally fair to the unaffiliated security holders (as defined in Rule 13e-3 of the Exchange Act), (2) determined that it is in the best interests of the Company’s stockholders, including the Unaffiliated Stockholders, and declared it advisable to enter into the Merger Agreement, (3) approved the execution and delivery by the Company of the Merger Agreement, the performance by the Company of its covenants and agreements contained therein and the consummation of the Merger and any other transactions contemplated thereby upon the terms and subject to the conditions contained therein, (4) resolved to recommend that the Company’s stockholders vote to adopt and approve the Merger Agreement and the consummation of the transactions contemplated thereby, in each case subject to the terms and conditions of the Merger Agreement and (5) directed that the Merger Agreement be submitted for adoption by the holders of shares of the Company’s capital stock entitled to vote thereon.

The Merger cannot be completed without both (a) the affirmative vote of the stockholders representing a majority of the aggregate voting power of the outstanding shares of Company common stock and shares of the Company’s Series B convertible preferred stock, par value $0.0001 per share, entitled to vote on the Merger Agreement, voting together as a single class, and (b) the affirmative vote of the stockholders representing a majority of the aggregate voting power of the outstanding shares of Company common stock beneficially owned by Unaffiliated Stockholders entitled to vote on the Merger Agreement.

Pursuant to General Instruction F to Schedule 13E-3, the information in the Proxy Statement, including all annexes thereto, is expressly incorporated by reference herein in its entirety, and responses to each item herein are qualified in their entirety by the information contained in the Proxy Statement and the annexes thereto. The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the items of Schedule 13E-3.

While each of the Filing Persons acknowledges that the Merger is a going private transaction for purposes of Rule 13E-3 under the Exchange Act, the filing of this Transaction Statement shall not be construed as an admission by any Filing Person, or by any affiliate of a Filing Person, that the Company is “controlled” by any of the Filing Persons and/or their respective affiliates.

The information concerning the Company contained in, or incorporated by reference into, this Transaction Statement and the Proxy Statement was supplied by the Company. Similarly, all information concerning each other Filing Person contained in, or incorporated by reference into, this Transaction Statement and the Proxy Statement was supplied by such Filing Person. No Filing Person is responsible for the accuracy of any information supplied by any other Filing Person.

Item 1.          Summary Term Sheet

Regulation M-A Item 1001

The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

Item 2.          Subject Company Information

Regulation M-A Item 1002

(a) Name and address. AgroFresh’s name, and the address and telephone number of its principal executive offices are:

AgroFresh Solutions, Inc.
One Washington Square
510-530 Walnut St., Suite 1350
Philadelphia, PA 19106
(267) 317-9139

(b) Securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Questions and Answers About the Special Meeting and the Merger—How many votes do I have?”

“The Special Meeting—Record Date and Quorum”

(c) Trading market and price. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

“Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

(d) Dividends. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

“Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

“The Merger Agreement—Conduct of Our Business Pending the Merger”

(e) Prior public offerings. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

“Other Important Information Regarding the Company—Prior Public Offerings”

(f) Prior stock purchases. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”

Item 3.          Identity and Background of Filing Person

Regulation M-A Item 1003(a) through (c)

(a) – (b) Name and Address of Each Filing Person; Business and Background of Entities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet—Parties to the Merger”

“Parties to the Merger—Parent and Merger Sub

“Other Important Information Regarding the Company”

“Other Important Information Regarding the PSP Entities”

“Where You Can Find More Information”

(c) Business and Background of Natural Persons.

“Other Important Information Regarding the Company—Directors and Executive Officers of the Company”

“Other Important Information Regarding the PSP Entities”

“Where You Can Find More Information”

Item 4.          Terms of the Transaction

Regulation M-A Item 1004(a) and (c) through (f)

(a) Material terms.

(1) Tender offer. Not applicable

(2) Merger or Similar Transactions.

(i) The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Effective Time of the Merger”

“Special Factors—Payment of Merger Consideration”

“The Merger Agreement—Conditions to the Merger”

(ii) The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger—As a common stockholder, what will I receive in the Merger?”

“Special Factors—Payment of Merger Consideration”

“The Merger Agreement—Treatment of Company Stock and Company Equity Awards”

(iii) The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Opinion of the Special Committee’s Financial Advisor”

“Special Factors—Unaudited Prospective Financial Information of the Company”

(iv) The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Questions and Answers About the Special Meeting and the Merger”

“The Merger Agreement—Stockholders Meeting”

“The Special Meeting—Vote Required”

(v) The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“The Merger Agreement—Treatment of Company Stock and Company Equity Awards”

“The Merger Agreement—Employee Benefits Matters”

“The Merger Agreement—Indemnification; Directors’ and Officers’ Insurance”

“The Merger Agreement—Surrender and Payment Procedures”

“The Voting and Support Agreement”

“Merger-Related Executive Compensation Arrangements (The Merger-Related Compensation Proposal—Proposal 3)”

(vi) The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

“Special Factors—Accounting Treatment”

(vii) The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

“Special Factors—Material U.S. Federal Income Tax Consequences of the Merger”

(c) Different terms. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“The Merger Agreement—Treatment of Company Stock and Company Equity Awards”

“The Merger Agreement—Employee Benefits Matters”

“The Merger Agreement—Indemnification; Directors’ and Officers’ Insurance”

“The Merger Agreement—Surrender and Payment Procedures”

“The Voting and Support Agreement”

“Merger-Related Executive Compensation Arrangements (The Merger-Related Compensation Proposal—Proposal 3)”

(d) Appraisal rights. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger—Am I entitled to rights of appraisal under the DGCL?”

“Special Factors—Appraisal Rights”

(e) Provisions for unaffiliated security holders. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Provisions for Unaffiliated Stockholders”

(f) Eligibility for listing or trading. Not applicable.

Item 5.          Past Contacts, Transactions, Negotiations and Agreements

Regulation M-A Item 1005(a) through (c) and (e)

(a)(1) – (2) Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Special Factors—Background of the Merger”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“Special Factors—Financing of the Merger”

“The Merger Agreement”

“The Voting and Support Agreement”

“Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”

(b) – (c) Significant corporate events; Negotiations or contacts. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“Special Factors—Financing of the Merger”

“The Merger Agreement”

“The Voting and Support Agreement”

Annex A—Agreement and Plan of Merger, dated as of November 21, 2022, by and among Project Cloud Holdings, LLC, Project Cloud Merger Sub, Inc., and AgroFresh Solutions, Inc.

Annex D—Voting and Support Agreement, dated as of November 21, 2022 by and among AgroFresh Solutions, Inc., Paine Schwartz Food Chain Fund V GP, L.P., Paine Schwartz Food Chain Fund V GP, Ltd., PSP AGFS Holdings, L.P., Paine Schwartz Partners, LLC, Kevin Schwartz, and, solely for the purposes set forth therein, Paine Schwartz Food Chain Fund V, L.P.

(e) Agreements involving the subject company’s securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Plans for the Company After the Merger”

“Special Factors—Financing of the Merger”

“The Merger Agreement”

“The Voting and Support Agreement”

“The Special Meeting—Vote Required”

“Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”

Annex A—Agreement and Plan of Merger, dated as of November 21, 2022, by and among Project Cloud Holdings, LLC, Project Cloud Merger Sub, Inc. and AgroFresh Solutions, Inc.

Annex D—Voting and Support Agreement, dated as of November 21, 2022 by and among AgroFresh Solutions, Inc., Paine Schwartz Partners, LLC, Paine Schwartz Food Chain Fund V GP, L.P., Paine Schwartz Food Chain Fund V GP, Ltd., PSP AGFS Holdings, L.P., Paine Schwartz Partners, LLC, Kevin Schwartz, and, solely for the purposes set forth therein, Paine Schwartz Food Chain Fund V, L.P.

Item 6.          Purposes of the Transaction and Plans or Proposals

Regulation M-A Item 1006(b) and (c)(1) through (8)

(b) Use of securities acquired. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Special Factors—Plans for the Company After the Merger”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Certain Effects of the Merger for Parent”

“Special Factors—Certain Effects on the Company if the Merger Is Not Completed”

“Special Factors—Payment of Merger Consideration”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

“Delisting and Deregistration of Common Stock”

(c)(1) – (8) Plans. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Plans for the Company After the Merger”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Certain Effects of the Merger for Parent”

“Special Factors—Certain Effects on the Company if the Merger Is Not Completed”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“Special Factors—Financing of the Merger”

“The Voting and Support Agreement”

“The Merger Agreement—Effects of the Merger; Directors and Officers; Articles of Incorporation; Bylaws”

“The Merger Agreement—Treatment of Company Stock and Company Equity Awards”

“The Merger Agreement—Conduct of Our Business Pending the Merger”

“Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

“Other Important Information Regarding the Company—Directors and Executive Officers of the Company”

“Delisting and Deregistration of Common Stock”

Annex A—Agreement and Plan of Merger, dated as of November 21, 2022, by and among Project Cloud Holdings, LLC, Project Cloud Merger Sub, Inc., and AgroFresh Solutions, Inc.

Item 7.          Purposes, Alternatives, Reasons and Effects

Regulation M-A Item 1013

(a) Purposes. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Plans for the Company After the Merger”

“Special Factors—Certain Effects of the Merger”

(b) Alternatives. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Opinion of the Special Committee’s Financial Advisor”

(c) Reasons. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Opinion of the Special Committee’s Financial Advisor”

“Special Factors—Unaudited Prospective Financial Information of the Company”

“Special Factors—Certain Effects of the Merger”

Annex B – Opinion of Perella Weinberg Partners LP

(d) Effects. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Plans for the Company After the Merger”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Certain Effects of the Merger for Parent”

“Special Factors—Certain Effects on the Company if the Merger Is Not Completed”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“Special Factors—Appraisal Rights”

“Special Factors—Material U.S. Federal Income Tax Consequences of the Merger”

“Special Factors—Accounting Treatment”

“Special Factors—Financing of the Merger”

“Special Factors—Fees and Expenses”

“Special Factors—Payment of Merger Consideration”

“The Merger Agreement—Effects of the Merger; Directors and Officers; Articles of Incorporation; Bylaws”

“The Merger Agreement—Treatment of Company Stock and Company Equity Awards”

“The Merger Agreement—Indemnification; Directors’ and Officers’ Insurance”

“The Merger Agreement—Employee Benefits Matters”

“The Merger Agreement—Conduct of Our Business Pending the Merger”

“Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

“Delisting and Deregistration of Common Stock”

Annex A—Agreement and Plan of Merger, dated as of November 21, 2022, by and among Project Cloud Holdings, LLC, Project Cloud Merger Sub, Inc., and AgroFresh Solutions, Inc.

Item 8.          Fairness of the Transaction

Regulation M-A Item 1014

(a) – (b) Fairness; Factors considered in determining fairness. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger —What vote is required to approve the Merger Agreement Proposal?”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Opinion of the Special Committee’s Financial Advisor”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

Annex B—Opinion of Perella Weinberg Partners LP

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated August 31, 2022, are attached hereto as Exhibit (c)(1) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated September 2, 2022, are attached hereto as Exhibit (c)(2) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated September 8, 2022, are attached hereto as Exhibit (c)(3) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP, dated September 19, 2022, are attached hereto as Exhibit (c)(4) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated October 18, 2022, are attached hereto as Exhibit (c)(5) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated November 4, 2022, are attached hereto as Exhibit (c)(6) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated November 21, 2022, are attached hereto as Exhibit (c)(7) and are incorporated herein by reference.

(c) Approval of security holders. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger—What vote is required to approve the Merger Agreement Proposal?”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“The Merger Agreement—Stockholders Meeting”

“The Merger Agreement—Conditions to the Merger”

“The Special Meeting”

Annex A—Agreement and Plan of Merger, dated as of November 21, 2022, by and among Project Cloud Holdings, LLC, Project Cloud Merger Sub, Inc. and AgroFresh Solutions, Inc.

(d) Unaffiliated representative. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Provisions for Unaffiliated Stockholders”

(e) Approval of directors. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Opinion of the Special Committee’s Financial Advisor”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“The Merger (The Merger Agreement Proposal—Proposal 1)”

(f) Other offers. Not applicable.

Item 9.          Reports, Opinions, Appraisals and Negotiations

Regulation M-A Item 1015

(a) – (b) Report, opinion or appraisal; Preparer and summary of the report, opinion or appraisal. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Opinion of the Special Committee’s Financial Advisor”

“Where You Can Find More Information”

Annex B—Opinion of Perella Weinberg Partners LP

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated August 31, 2022, are attached hereto as Exhibit (c)(1) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated September 2, 2022, are attached hereto as Exhibit (c)(2) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated September 8, 2022, are attached hereto as Exhibit (c)(3) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP, dated September 19, 2022, are attached hereto as Exhibit (c)(4) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated October 18, 2022, are attached hereto as Exhibit (c)(5) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated November 4, 2022, are attached hereto as Exhibit (c)(6) and are incorporated herein by reference.

Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated November 21, 2022, are attached hereto as Exhibit (c)(7) and are incorporated herein by reference.

(c) Availability of documents. The reports, opinions or appraisals referenced in this Item 9 will be made available for inspection and copying at the principal executive offices of the Company during its regular business hours by any interested equity security holder of the Company or representative who has been so designated in writing.

Item 10.          Source and Amounts of Funds or Other Consideration

Regulation M-A Item 1007

(a) – (b) Source of funds; Conditions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Special Factors—Financing of the Merger”

“The Merger Agreement—Financing; Cooperation with Debt Financing”

Equity Commitment Letter, dated November 21, 2022, by and between Paine Schwartz Food Chain Fund VI, L.P. and Project Cloud Holdings, LLC, is attached hereto as Exhibit (d)(4) and is incorporated herein by reference.

(c) Expenses. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Special Factors—Fees and Expenses”

“The Merger Agreement—Termination”

“The Merger Agreement—Company Termination Fee”

“The Merger Agreement—Expenses”

(d) Borrowed funds. Not applicable.

Item 11.          Interest in Securities of the Subject Company

Regulation M-A Item 1008

(a) Securities ownership. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“Other Important Information Regarding the Company—Security Ownership of Certain Beneficial Owners and Management”

(b) Securities transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”

“Other Important Information Regarding the Company—Prior Public Offerings”

Item 12.          The Solicitation or Recommendation

Regulation M-A Item 1012(d) and (e)

(d) Intent to tender or vote in a going-private transaction. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“Special Factors—Intent to Vote in Favor of the Merger”

“Special Factors—PSP’s Obligation to Vote in Favor of the Merger”

“The Merger Agreement—PSP Vote”

“The Special Meeting—Vote Required”

“The Voting and Support Agreement”

Annex D—Voting and Support Agreement, dated as of November 21, 2022 by and among AgroFresh Solutions, Inc., Paine Schwartz Partners, LLC, Paine Schwartz Food Chain Fund V GP, L.P., Paine Schwartz Food Chain Fund V GP, Ltd., PSP AGFS Holdings, L.P., Paine Schwartz Partners, LLC, Kevin Schwartz, and, solely for the purposes set forth therein, Paine Schwartz Food Chain Fund V, L.P.

(e) Recommendation of others. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Position of the PSP Entities as to the Fairness of the Merger”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Purpose and Reasons of the PSP Entities for the Merger”

“The Merger (The Merger Agreement Proposal—Proposal 1)”

Item 13.          Financial Information

Regulation M-A Item 1010(a) through (b)

(a) Financial statements. The audited consolidated financial statements of the Company for the fiscal years ended December 31, 2021 and 2020 are incorporated herein by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 9, 2022 (see “Item 8 - Financial Information” beginning on page 39) and the unaudited condensed consolidated financial statements of the Company for the quarterly period ended September 30, 2022, are incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed on November 9, 2022 (see “Item 1 - Condensed Consolidated Financial Statements” beginning on page 3).

The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Special Factors—Certain Effects of the Merger”

“Special Factors—Unaudited Prospective Financial Information of the Company”

“Other Important Information Regarding the Company—Book Value per Share”

“Where You Can Find More Information”

(b) Pro forma information. Not applicable.

Item 14.          Persons/Assets, Retained, Employed, Compensated or Used

Regulation M-A Item 1009

(a) – (b) Solicitations or recommendations; Employees and corporate assets. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Questions and Answers About the Special Meeting and the Merger”

“Special Factors—Background of the Merger”

“Special Factors—Reasons for the Merger; Recommendation of the Special Committee”

“Special Factors—Approval and Recommendations of the Board; The Company’s Position as to the Fairness of the Merger to Unaffiliated Stockholders”

“Special Factors—Purpose and Reasons of the Company for the Merger”

“Special Factors—Fees and Expenses”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“The Special Meeting—Solicitation of Proxies; Payment of Solicitation Expenses”

Item 15.          Additional Information

Regulation M-A Item 1011(b) and (c)

(b) Golden Parachute Compensation. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

“Summary Term Sheet”

“Special Factors—Certain Effects of the Merger”

“Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

“The Merger Agreement—Treatment of Company Stock and Company Equity Awards”

“Merger-Related Executive Compensation Arrangements (The Merger-Related Compensation Proposal—Proposal 3)”

(c) Other material information. The information set forth in the Proxy Statement, including all annexes thereto, is incorporated herein by reference.

Item 16.          Exhibits

Regulation M-A Item 1016(a) through (d), (f) and (g)

(a)(1) Preliminary Proxy Statement of AgroFresh Solutions, Inc. (the “Proxy Statement”) (included in the Schedule 14A filed concurrently with the SEC and incorporated herein by reference).

(a)(2) Form of Proxy Card (included in the Proxy Statement and incorporated herein by reference).

(a)(3) Letter to AgroFresh Solutions, Inc. Stockholders (included in the Proxy Statement and incorporated herein by reference).

(a)(4) Notice of Special Meeting of Stockholders (included in the Proxy Statement and incorporated herein by reference).

(a)(5) Current Report on Form 8-K, dated November 22, 2022 (included in Schedule 14A filed on November 22, 2022 and incorporated herein by reference).

(a)(6) Current Report on Form 8-K, dated November 23, 2022 (included in Schedule 14A filed on November 23, 2022 and incorporated herein by reference).

(c)(1) Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated August 31, 2022.

(c)(2) Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated September 2, 2022.

(c)(3) Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated September 8, 2022.

(c)(4) Discussion Materials of Perella Weinberg Partners LP, dated September 19, 2022.

(c)(5) Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated October 18, 2022.

(c)(6) Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated November 4, 2022.

(c)(7) Discussion Materials of Perella Weinberg Partners LP for the Special Committee, dated November 21, 2022.

(c)(8) Opinion of Perella Weinberg Partners LP, dated November 21, 2022 (incorporated herein by reference to Annex B of the Proxy Statement).

(d)(1) Agreement and Plan of Merger, dated as of November 21, 2022, by and among Project Cloud Holdings, LLC, Project Cloud Merger Sub, Inc. and AgroFresh Solutions, Inc. (incorporated herein by reference to Annex A of the Proxy Statement).

(d)(2) Voting and Support Agreement, dated November 21, 2022, by and between AgroFresh Solutions, Inc., Paine Schwartz Partners, LLC, Paine Schwartz Food Chain Fund V GP, L.P., Paine Schwartz Food Chain Fund V GP, Ltd., PSP AGFS Holdings, L.P., Paine Schwartz Partners, LLC, Kevin Schwartz, and, solely for the purposes set forth therein, Paine Schwartz Food Chain Fund V, L.P. (incorporated herein by reference to Annex D of the Proxy Statement).

(d)(3) Limited Waiver, dated as of October 26, 2022, by and between AgroFresh Solutions, Inc. and Paine Schwartz Partners, LLC (filed as Exhibit 10.1 to AgroFresh Solutions, Inc.’s Current Report on Form 8-K, filed October 27, 2022 and incorporated herein by reference).

(d)(4) Equity Commitment Letter, dated November 21, 2022, by and between Paine Schwartz Food Chain Fund VI, L.P. and Project Cloud Holdings, LLC.

(f) Section 262 of the General Corporation Law of the State of Delaware (incorporated herein by reference to Annex C of the Proxy Statement).

107 Filing Fee Table.

SIGNATURES

After due inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: December 21, 2022

 
AGROFRESH SOLUTIONS, INC.
     
 
By:
/s/ Clinton A. Lewis, Jr.
   
Name: Clinton A. Lewis, Jr.
   
Title: Chief Executive Officer

 
PROJECT CLOUD MERGER SUB, INC.
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: President and Chief Executive Officer

 
PROJECT CLOUD HOLDINGS, LLC
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: President and Chief Executive Officer

 
PAINE SCHWARTZ FOOD CHAIN FUND V, L.P.
     
 
By:
Paine Schwartz Food Chain Fund V GP, L.P.
 
Its:
General Partner
     
 
By:
Paine Schwartz Food Chain Fund V GP, Ltd.
 
Its:
General Partner
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: Director

 
PAINE SCHWARTZ FOOD CHAIN FUND V GP, L.P.
     
 
By:
Paine Schwartz Food Chain Fund V GP, Ltd.
 
Its:
General Partner
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: Director

 
PAINE SCHWARTZ FOOD CHAIN FUND V GP, LTD.
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: Director

 
PAINE SCHWARTZ FOOD CHAIN FUND VI, L.P.
     
 
By:
Paine Schwartz Food Chain Fund VI GP, L.P.
 
Its:
General Partner
     
 
By:
Paine Schwartz Food Chain Fund VI UGP, LLC
 
Its:
General Partner
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: Managing Member

 
PSP AGFS HOLDINGS, L.P.
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: Chief Executive Officer

 
PAINE SCHWARTZ PARTNERS, LLC
     
 
By:
Paine Schwartz Partners Founders, L.P.
 
Its:
Manager
     
 
By:
Paine Schwartz Partners Founders GP, LLC
 
Its:
General Partner
     
 
By:
/s/ Kevin Schwartz
   
Name: Kevin Schwartz
   
Title: Managing Member



Exhibit (c)(1)


 Summary Perspectives on Financial Model  Project OptimusPrime  August 31, 2022 
 

 Summary Takeaways on Financial Model Provided 8/25  Methodology  Management maintains and updates an annual rolling 5-year financial model  In light of three major product launches in 2026E, management developed a 10-year P&L projection to account for the Company’s long-term growth opportunity  Each product revenue forecast is anchored on historical trends (mix of market size, volume, pricing, penetration) and latest perspectives of product managers  Revenue  Company’s legacy product, SmartFresh Apple, is expected to steadily erode over time due to pricing pressures from generics entering the market offset by new registrations in new crops and geographies  2026E represents a critical year for growth driven by 1) Harvista approval in Europe and 2) expected launches of Novel Antimicrobials (“BoB”) and Novozymes Biologics   Antimicrobials expected to be a large contributor to long-term growth, representing 40%+ of total revenue by 2032E  Expenses  Diversification products are lower margin in nature vs. SmartFresh Apple. Total gross margin is expected to decline over time as Company executes on its diversification efforts  R&D and S&M as a % of revenue largely held flat through 2026E; operating leverage seen primarily from efficiencies within G&A  R&D targets 7%-8% of revenue in the near- to medium-term, reflecting continued investment in new product launches   Initial diligence session with PWP on 08/29; summary perspectives below: 
 

 Key Questions  In general, provide context to the process of developing and updating the long-range plan. How is each product line forecasted and validated internally?   Provide commentary on the expected erosion of SmartFresh Apple and the factors driving customer retention versus cheaper generics in the market today   Discuss risks related to competition within SmartFresh Diversification – should we expect similar erosion if and when generics enter the market?  2026E represents a critical year of growth – please provide commentary on the expected new major product launches of Harvista, Novel Antimicrobial and Novozymes Biologics  What is your confidence level in and key risks to achieving the product launch schedule laid out in the plan?  Please discuss gross margin evolution as it relates to continued diversification into lower margin products – are there certain products of focus to maintain a higher gross margin?   Provide color on operating leverage expected from R&D, S&M and G&A over the forecast period 
 

 SmartFresh Apple revenue anticipated to erode over time due to pricing pressures from generics entering the market   Antimicrobials projected to be a large contributor to revenue, primarily driven by anticipated Novel Antimicrobial and Novozymes Biologics product launches in 2026  Total gross margin forecasted to decline as Company diversifies into lower margin products  R&D and S&M as a % of revenue largely held flat through 2026E; operating leverage seen primarily from efficiencies within G&A  Management Finance Case: P&L  Source: Company financials  ($ in millions)  PWP commentary  1  2  3  4  1  2  3  4 
 

 Management Finance Case: Revenue and Gross Margin Detail  Source: Company financials  1  1  2  Novel Antimicrobials and Novozymes Biologics contribute a large amount to growth and revenue in the outyears  Diversification growth products have significantly lower margins than legacy SmartFresh Apple  PWP commentary  1  2 
 

 Management Finance Case: Cash Flow Statement  Source: Company financials  ($ in millions) 
 

 Management Finance Case: COGS Drivers  Source: Company financials 
 

 Company TAM Penetration Overview by Selected Products  Source: Diligence materials received by Company management on 08/24/22  Note: (1) TAM represents long-term TAM; % penetration represents Company penetration of TAM at maturity  (1)  Management assumes steady increase in market penetration over time 
 

 Company New Product Launch Assumptions  Source: Company materials 
 

 Legal Disclaimer  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service.  The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors.   Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction. 
 


Exhibit (c)(2)

 Preliminary Perspectives  Project OptimusPrime  September 2, 2022 
 

 Table of Contents  Public Market Data & Analysis  Review of Management Long Range Plan  Preliminary Valuation Perspectives  Preliminary Process Alternatives  Next Steps  Appendix 
 

 Public Market Data & Analysis  
 

 Key Considerations for OptimusPrime Public Equity  Limited float and illiquid currency  Substantial ownership position by Dow combined with insiders limits public float to ~55% of shares outstanding  L3M average daily trading volume of ~25k shares / day, or less than 0.1% of free float  Overhang from Paine Schwartz Partners and Dow  PSP currently holds ~39% (and growing) on an as-converted basis in the form of Series B convertible preferred securities  Dow owns nearly 40% of the Company’s common stock (~25% post-conversion of Series B), giving it a strong influence on the outcome of any vote  Continued value erosion from convertible preferred  The Series B convertible preferred shares impact the value of the Company’s common shares and its ability to pursue strategic alternatives  The 16%+ dividend (split between PIK and cash interest) adversely impacts common shareholders through (1) the cash flow available to the common and (2) dilution  Limited equity research coverage  Company is currently covered by 4 brokers; 3 out of the 4 brokers project to 2023E only, limiting the ability of investors to fully assess the Company’s long(er)-term value creation prospects  Historical performance since De-SPAC  Company has traded down nearly 80% since its De-SPAC, reflecting the competitive and operational challenges it has faced thus far and the growing overhang from its capital structure and shareholder base  A  B  D  E  C 
 

 Relative Stock Price Performance vs. Peers  Source: Capital IQ as of 08/30/22  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen   (1) Reflects performance since 06/18/2018   (1)  Share Price performance indexed to Company (LTM) 
 

 Ev / NTM EBITDA – Since January 2019  Historical Valuation Multiples  Source: FactSet as of 08/30/2022  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen  Company has historically traded at ~7.0x EV / NTM EBITDA since January 2019 
 

 Historical and Consensus Projected Financials  REVENUE  GROSS PROFIT  Adjusted EBITDA (Non-gaap)  Free Cash Flow (non-Gaap)(1)  ($ in millions)  Source: FactSet, S&P Capital IQ as of 08/30/2022  Notes: Metrics are based on calendar year financials   (1) FCF calculated as Cash Flow from Operating Activities less Capital Expenditures   After two consecutive years of revenue declines, growth appears to have been re-invigorated; however, SmartFresh Apple is facing continued gradual erosion  Gross profit and gross margin have eroded meaningfully since 2019; expected diversification will drive further percentage erosion, but is expected to grow gross profit in absolute dollars, such that 2023 will be flat vs. 2019  Company achieves mid-high 30% EBITDA margins, however, EBITDA growth has been stagnant  Company produces high cash flow margins, benefitting from its asset-light and low CapEx operating model 
 

 WALL STREET SENTIMENT  Average # of Brokers  Potential Catalysts  Key Risks  Continue to diversify revenue away from SmartFresh Apple by leveraging technology, deep registration and regulatory assets  Strong growth initiatives for Vitafresh and FreshCloud solutions that are set to leverage significant global customer base   New partnership announced with Novozymes represents a long-term growth opportunity   Attractive margin profile supported by asset-light and low CapEx operating model  A large portion of the company’s revenue comes from SmartFresh product, which is based on one active ingredient  Continued erosion of SmartFresh Apple from competition   December 2024 term loan maturity  Outstanding series B convertible preferred represents high dilution risk along with ongoing cash dividend payments   Decline in gross margins as Company diversifies into lower margin products  Susceptibility to adverse weather events   Source: Wall Street research, FactSet as of 08/30/2022  Note: (1) Current price of $1.55 as of 08/30/2022  Equity Analyst View of OptimusPrime Stock  142% premium to current price(1) 
 

 Equity Analyst Valuation Perspectives  Source: Wall Street equity research  Notes: Fiscal year ends Dec. 31    (1) Current price of $1.55 as of 08/30/2022  Date  08/29/2022  08/11/2022  08/10/2022  08/09/2022  Methodology  EV / CY2022E EBITDA: 8.9x  DCF   15.8% discount rate (WACC)  P / FCF CY2022E: 9.0x  EV / CY2022E EBITDA: 7.0-7.5x  Latest Projection Year  2023E  2032E  2023E  2023E  Target Price  $4.50  $5.00  $3.00  $2.25  Premium / (Discount) to Current(1)  190.3%  222.6%  93.5%  45.2%  Rating  Buy  Buy  Buy  Hold  Rationale  “Looking towards 2H 2022, we anticipate a solid y/y increase driven by easier comparable (lower harvests last year due to weather) and incremental diversification growth.”  “In the short term, we expect [Company] to gain  market share in the post-harvest markets and expect the company to be opportunistically acquisitive in the mid-to-long term.”  “The traditionally seasonally weak second quarter far exceeded our expectations this year on the top and bottom lines, and growth across its emerging portfolio set record levels.”   “It might take some time for earnings to break out while [Company] deals with higher leverage and  Illiquidity.” 
 

 Meet / Miss Analysis (vs. Wall Street): Revenue and EBITDA  Source: Company filings, FactSet  ($ in millions)  Revenue  Adjusted EBITDA  Company has been more consistent with earnings beats since the appointment of its new management team in 2021 
 

 Overview of Current Capital Structure and Liquidity  Liquidity Analysis(3)(4)  Capital Structure  Source: Company filings, market data as of 08/30/2022  Notes: (1) 600 bps at <3.50x Net Leverage, 625 bps >3.50x Net Leverage   (2) Includes accumulated PIK   (3) Based on Management Finance Case, assumes RCF and TLB are extended at L+700 and Convertible Preferred Stock is not refinanced   (4) Does not assume recapitalization of convertible preferred   (5) Includes FX costs of $4.3M  (1)  ($ in millions)  (2)  (5) 
 

 Key Terms of Series B Convertible Preferred Stock  Conversion  The Series B Preferred Stock is convertible into Common Stock at the election of the holder at any time at an initial Conversion Price of $5.00 / share  Voting   Entitled to vote with Common Stock, number of shares based on the Conversion Price  Redemption Price  MOIC of 1.50x on or before July 27, 2021  MOIC of 1.75x on or before July 27, 2022  MOIC of 2.00x from and after July 27, 2022  MOIC  All cash redemption payments (including all cash dividends paid) divided by the difference of Liquidation Value minus OID(1)  Alternative Redemption Price  Redemption at 100% of Liquidation Value, plus all accumulated dividends  Change of Control  Change of control means (i) the sale of all or substantially all of the assets of Company to a 3rd party, (ii) a transaction by which any Person or group, other than PSP, is or becomes the beneficial owner of 50% or more of voting power, or (iii) the consolidation, merger or other combination of Company with or into any Person or Persons (unless no change in voting power post-combination or the merger effected solely for purposes of changing jurisdiction of incorporation)  In the event of a Change of Control, Company would be required to make an offer to repurchase all of the preferred stock for cash consideration per share equal to the greater of (i) the then-applicable Redemption Price or, in the event of a Change of Control after July 27, 2023, the Alternative Redemption Price, and (ii) the amount such holders would be entitled to receive at such time if the preferred stock were converted into common stock  Elective Redemption  In first 3 years of issuance, Company can choose to redeem all preferred stock at the designated redemption price or a partial redemption (of at least $25M and in $1M increments thereafter) that leaves at least $75M outstanding  After the first 3 years of issuance, Company may redeem (i) all preferred stock, (ii) in any 12 month period, no more than 50% of the then outstanding preferred stock for a price per share equal to the Alternative Redemption Price (if minimum volume and price redemption conditions are met) or the greater of the Alternative Redemption Price and the 2.0x Redemption Price (if minimum volume and price redemption conditions are not met)  Minimum Volume and Price Redemption Conditions: 20-day VWAP prior to the Redemption Date is equal to or greater than 100,000 shares and the Current Market Price is equal to or greater than $8.00  Source: Company Filings  Note: (1) MOIC calculation is equitably adjusted for the Decco Redemption 
 

 Review of Management Long Range Plan 
 

 Model Summary Takeaways  Methodology  Management maintains and updates an annual rolling 5-year financial model  In light of three major product launches in 2026E, management developed a 10-year P&L projection to account for the Company’s long-term growth opportunity  Each product revenue forecast is anchored on historical trends (mix of market size, volume, pricing, penetration)  Product revenue forecast is prepared by strategic marketing  Not a true “bottoms-up analysis” built on a customer basis  Revenue  Company’s legacy product, SmartFresh Apple, is expected to steadily erode over time due to pricing pressures from generics entering the market offset by new registrations in new crops and geographies  No erosion for other 1-MCP products assumed  2026E represents a critical year for growth driven by 1) Harvista approval in Europe and 2) expected launches of Novel Antimicrobials (“BoB”) and Novozymes Biologics   New products are based on assumed penetration and adoption curves; unclear if these are based on “Customer demand or needs”  Antimicrobials expected to be a large contributor to long-term growth, representing 40%+ of total revenue by 2032E compared with ~19% in 2026E  Additionally, gross profit attributable to Antimicrobials expected to grow from ~11% in 2026E to ~38% in 2032E, largely driven by 75%+ gross margin for Novozymes Biologics ($90M+ revenue in 2032E) compared to an overall gross margin of ~65%  Expenses  Diversification products are lower margin in nature vs. SmartFresh Apple. Total gross margin is expected to decline over time as Company executes on its diversification efforts  R&D and S&M as a % of revenue largely held flat through 2026E; operating leverage seen primarily from efficiencies within G&A  R&D targets 7%-8% of revenue in the near- to medium-term, reflecting continued investment in new product launches   Antimicrobial expected also to comprise an increasingly significant portion of profitability, representing 37%+ of gross profit by 2023E (up from ~11% in 2026E)  Initial diligence session with PWP on 08/29, followed by a second diligence session with PWP and the Special Committee on 08/31; summary perspectives below: 
 

 SmartFresh Apple revenue anticipated to erode over time due to pricing pressures from generics entering the market   Antimicrobials projected to be a large contributor to revenue, primarily driven by anticipated Novel Antimicrobial and Novozymes Biologics product launches in 2026  Total gross margin percentage forecasted to decline as Company diversifies into lower margin products  R&D and S&M as a % of revenue largely held flat through 2026E; operating leverage seen primarily from efficiencies within G&A  Management Finance Case: P&L  Source: Company financials  ($ in millions)  PWP commentary  1  2  3  4  1  2  3  4 
 

 Management Finance Case: Revenue and Gross Margin Detail  Source: Company financials  1  1  2  Novel Antimicrobials and Novozymes Biologics contribute a large amount to growth and revenue in the outyears  Diversification growth products have significantly lower margins than legacy SmartFresh Apple  PWP commentary  1  2 
 

 Company TAM Penetration Overview by Selected Products  Source: Diligence materials received by Company management on 08/24/22  Note: (1) TAM represents long-term TAM; % penetration represents Company penetration of TAM at maturity  (1)  Management assumes steady increase in market penetration over time 
 

 Limited estimates available 2024E+; only 1 broker available  P&L Comparison: Consensus Estimates vs. Management Finance Case  Source: FactSet, Capital IQ, Company Filings, Company financials  Notes: (1) Broker estimates as of 08/30/22   (2) Represents Finance case in management projections received on 08/25/22  ($ in millions)  Near-term management projections are in-line with consensus estimates. Difficult to compare 2024E+ projections due to lack of broker estimates 
 

 Preliminary Valuation Perspectives 
 

 Preliminary Valuation Approach Considerations  PWP utilized a combination of extrinsic and intrinsic valuation methodologies to form initial valuation perspectives on the Company  For the extrinsic valuation methodologies, the Company lacks a “perfect” public comp and precedent transaction  PWP believes there is no post-harvest ag-tech specializing in specialty crops in the public markets (the closest comps e.g., Apeel, Pace, etc. are independent or private subsidiaries)  As a result, PWP identified three groups of potential comps: traditional Ag Chemicals, High Value Specialties and Food Safety / Security  PWP analyzed the Company’s intrinsic value through a DCF and LBO   A 10-year DCF was utilized given long-term growth opportunities starting in 2026E  As a result, new growth products (Harvista, Novel Antimicrobials (“BoB”), Novozymes Biologics) drive a significant portion of the terminal value   PWP additionally looked at an illustrative market discount case which excludes revenue from new growth products and holds VitaFresh Botanicals Coatings and FreshCloud relatively stable starting 2025E to adjust for risks to achieving the long-term 10-year plan  The LBO is modelled over a 5-year time horizon, representing the holding period for typical sponsors   PWP primarily focused on EBITDA and EBITDA multiples given the maturity and robust cash flow generation of Company  Separately, PWP also performed present value of future share price and precedent premia analyses  
 

 Summary of Valuation Methodologies and Approach  Valuation Methodology  Description  Market Reference  52 Week Trading  Range reflects Company’s 52-week low and high share prices as of 08/30/2022   Research Analyst Targets  Range reflects low and high analyst share price targets as of 08/30/2022  Low and high analyst share price targets per BMO and HC Wainwright, respectively  Discounted by 1-year at Company’s cost of equity  Comparable Public Companies  Consensus Metrics  EV / 2022E EBITDA  Applied relevant EV / 2022E EBITDA peer multiple ranges to Company’s 2022E EBITDA per Consensus estimates  Given no change of control, convertible preferred treated at face value in share price calculation  EV / 2023E EBITDA  Applied relevant EV / 2023E EBITDA peer multiple ranges to Company’s 2023E EBITDA per Consensus estimates  Given no change of control, convertible preferred treated at face value in share price calculation  Management Finance Case  EV / 2022E EBITDA  Applied relevant EV / 2022E EBITDA peer multiple ranges to Company’s 2022E EBITDA per Management Finance Case  Given no change of control, convertible preferred treated at face value in share price calculation  EV / 2023E EBITDA  Applied relevant EV / 2023E EBITDA peer multiple ranges to Company’s 2023E EBITDA per Management Finance Case  Given no change of control, convertible preferred treated at face value in share price calculation  Precedent Transactions  EV / LTM EBITDA  Applied relevant EV / LTM EBITDA precedent transactions multiple ranges (~25th – ~50th percentile) to Company’s LTM EBITDA  Assumes convertible preferred valued at 2.0x MOIC given change of control scenario  Intrinsic Valuation  Management Finance Case  DCF  Discounted Company’s unlevered free cash flows per Management Finance Case from 2022 to 2032 to present value using an assumed discount rate of 10.5% – 14.5%  Terminal multiple range of 7.0x – 9.0x  Given no change of control, convertible preferred treated at face value in share price calculation  LBO  Assumed a 5-year hold period with a target IRR of 20.0% – 30.0%  Management Finance Case utilized for financial projections  Exit multiple range of 8.0x – 10.0x  Assumes convertible preferred valued at 2.0x MOIC given change of control scenario  Market Discount Case  DCF  Assumes no contribution from growth products (Novel Antimicrobials and Novozymes Biologics)  Assumes FreshCloud and VitaFresh grow 3% 2025E+  Terminal multiple range of 7.0x – 9.0x  Given no change of control, convertible preferred treated at face value in share price calculation 
 

 Preliminary Valuation Summary  Current Share Price: $1.55  Notes: Share price as of 08/30/22   (1) Broker price targets represent 12-month targets; prices discounted 12 months from date of publication to 08/30/22; assumes cost of equity of 15.25%   (2) Excludes impact of Novel Antimicrobials and Novozymes Biologics revenue and gross margin forecasts from management finance case and assumes 3% YoY growth for VitaFresh Botanicals Coatings and FreshCloud starting 2025E  Highly preliminary & confidential – Illustrative Analyses for Discussion  (2)  (1) 
 

 Public Comparable Companies Analysis  Source: S&P Capital IQ and FactSet as of 08/30/22, company financials  Notes: Metrics are based on calendar year financials; EV / Revenue, EV / EBITDA, and P / E multiples greater than 50.0x, 75.0x, and 100.0x   respectively are considered “NM”. Negative multiples are considered “NM”. “NA” indicates that a value was not available  ($ in millions, except per share values)  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Select Company Valuation Benchmarking  CY2023E EV / EBITDA  Source: FactSet, S&P Capital IQ as of 08/30/22  Notes: Metrics are based on calendar year financials; EV / Revenue multiples greater than 50.0x are considered “NM”. Negative multiples considered “NM”. “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm   (1) FCF yield calculated as CFO less CapEx divided by Market Capitalization   (2) Assumes preferred dividend payment of $14.3M per Management Case  AgChem Tech  High Value Specialties  Food Safety / Security  CY2023E FCF Yield(1)  AgChem Tech  High Value Specialties  Food Safety / Security  3%  FCF Yield including 2023E Debt Repayment and Preferred Dividend Payment(2) 
 

 Select Company Operational Benchmarking  CY2022E Ebitda margin  Source: FactSet, S&P Capital IQ as of 08/30/22  Notes: Metrics are based on calendar year financials; Debt / LTM EBITDA and Net Debt / LTM EBITDA multiples with negative EBITDA are considered “NM.” “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm     CY2021A – CY2023E Revenue CAGR  CY2022E Gross margin  AgChem Tech  High Value Specialties  Food Safety / Security 
 

 Select Precedent Transactions  Source: Company filings, Moody’s, press releases  Notes: (1) Reflects forward multiple due to data availability   (2) Assumes 25% EBITDA Margin per JBT Investor Presentation  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (1)  (1)  (2)  (1)  (1) 
 

 Analysis at Various Share Prices  Source: FactSet, Capital IQ, Company Filings, Company financials  Notes: (1) Represents change of control amount for Paine Schwartz Partners convertible preferred equity   (2) Multiples in AVP reflect convertible preferred at liquidation preference, assuming 2.0X MOIC  ($ in millions, except share price)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (2)  (2)  (2) 
 

 Precedent Premia Analysis  Analysis for U.S. companies acquired since 2017 indicates targets receiving higher premia the steeper the discount to 52-week high  Highly preliminary & confidential – Illustrative Analyses for Discussion  Source: FactSet as of 08/30/2022  Notes: Unaffected premiums shown for acquisitions since 01/01/2017 with a transaction value between $100M – $3B and targets in the United States; excludes MOEs and transactions with targets industries of Energy, Insurance, Mining, Oil & Gas, REITs, Railroads, and Utilities   The Company is currently trading at 64% of its 52W High   (1) % of 52W High reflects share price as of unaffected date divided by 52W High as of unaffected date  
 

 Preliminary Process Alternatives  
 

 Assessment of Preliminary Alternatives  Description  PWP Assessment  Engage with PSP   Evaluate and negotiate potential transaction with PSP  As a result of owning the convertible preferred, PSP represents the buyer with the most leverage from a financial perspective  Run Auction Sale Process  Pursue sale with outreach to both strategic and financial parties  PSP redemption requirements under a change of control may be unattractive to potential buyers  Valuation likely to reflect risks of executing on strategic plan  Need to navigate consideration for PSP’s position in the Company  Status Quo / Refinance  Company focuses on execution of its long-term plan   Evaluating potential refinancing options for term loan due in 2024 and Series B Convertible Preferred  Currently at ~39% ownership on an as-converted basis, PSP’s quarterly PIK dividend continues to further dilute shareholders over time  High dividend rate and governance requirements of Series B represents overhang to share price  Significant Dow position in common represents a secondary overhang  Upcoming term loan maturity in 2024 also needs to be addressed in early 2023 before the Company’s Going Concern status comes into question in Q4 2023  Convertible preferred has no maturity and high breakage costs in the near-term; a refinancing in 2024-2025 becomes more attractive when breakage costs become negligible over time  A  B  C 
 

 Traditional sponsor irr / moic sensitivity(2)  Traditional sponsor commentary  Paine schwartz partners IRR / MOIC sensitivity(1)  Paine schwartz partners commentary  Comparison of IRR / MOIC: Paine Schwartz vs. Other Sponsors  Paine Schwartz Partners returns are more attractive compared to other traditional financial sponsors due to the lack of breakage costs  Paine Schwartz is not only expected to receive an attractive ~29% IRR from an illustrative purchase price of $2.50 / share, but also will have received ~15% IRR from the initial Series B Convertible Preferred investment  Traditional sponsor returns are less attractive given sponsors are required to pay breakage costs of $81M as of 12/31/22  A  Source: Company financials   Notes: Analysis utilizes figures from management finance case and assumes transaction close of 12/31/22   (1) Assumes convertible preferred valued at face value at time of transaction close (no breakage costs)   (2) Assumes convertible preferred valued at 2.0x MOIC (inclusive of breakage costs) 
 

 Potential Private Equity and Strategic Buyers for Auction Process  Observations On Market environment and current trends  Focus on reduction of food waste / conservation of resources  Changing dietary trends towards fresh fruit and produce  Increasing supply chain risks and disruptions  Increasing demand for data in terms of traceability, quality and food safety   Strategics  Potential buyers  Sponsors  B 
 

 Scheduled Principal repayments and amortization  Need to Address Upcoming 2024 Scheduled Principal Repayments  PWP Assessment  Upcoming term loan maturity in 2024 also needs to be addressed in early 2023 before the Company’s Going Concern status comes into question in Q4 2023  Source: Company Filings, FactSet  Note: (1) Represents remaining principal in 2022 as of Q2-22A   (2) Figures from management model   (3) Interest includes cash interest and cash dividend payments on convertible preferred from management model  Moody’s Credit Rating: B3  S&P Credit Rating: B-  (1)  (2)  (2)  (3)  C  Revenue Haircut Sensitivity – Impact on Ability to Meet Financing Commitments  Revenue Haircut  10%   20%   30%   37%   2027E Revenue   $258   $229   $201   $181   2027E EBITDA   102   90   79   71   2027E Ending Cash Balance   77   52   27   10   Assumes ending 2022 cash balance of ~$60M and $10M minimum cash balance to operate going forward  Haircuts management case total revenue for 2023E to 2027E while holding margins constant  Analysis implies the Company has considerable headroom on its topline forecast while maintaining the ability to service its debt and pay its preferred dividends 
 

 commentary  Convertible Preferred Accretes Over Time Through PIK Interest  Dividend Rates  16% per annum, of which 50% is payable in cash and 50% is payable in kind for the first year after the closing date, after which 50% will be payable in cash, 37.5% will be payable in kind and 12.5% will be payable in cash or in kind at the company’s discretion (management model assumes 50% cash and 50% PIK in forecast period)  PSP has the right to appoint an additional member to the Board commensurate with their as-converted ownership stake   If PSP has over 50% of Directors on the Board and Dow owns at least 20% of AgroFresh’s as-converted common stock, Dow has the right to designate an additional member to the Board  There is also one share of Series A Preferred Stock owned by Dow, entitling Dow to appoint one director to the Board   Source: Company Filings  Notes: (1) Assumes preferred stock is converted at a conversion price of $5.00 and the amount of shares outstanding remains constant from Q2-22A   (2) Reflects the average for the year, with a 10% cash dividend rate for Q3 2021, Q4 2021 and Q1 2022  ($ in millions)  Paine Schwartz’s ownership expected to cross 50% ownership on an as-converted basis by Q1 2028  (1)  C  (2)  (2) 
 

 Present Value of Future Share Price (Status Quo w/ No Breakage Costs)  Source: Company financials  Notes: Assumes valuation date of 12/31/22; uses current FDSO, NCI, market capitalization and EV; assumes cost of equity of 15.25%. Convertible Preferred    taken at face value in status quo scenario (i.e., no breakage costs included)  Significant common shareholder dilution and impact in the near term from the convertible preferred  Highly preliminary & confidential – Illustrative Analyses for Discussion  C 
 

 Refinancing Considerations: Series B Convertible Preferred  Source: Company financials  Note: (1) Based on 56.3mm diluted shares outstanding  Growth of Equity Value Over time @7.0x EV / EBITDA  Implied Future Share   Price(1)  Net Debt  Convert. Pref.  Equity  Favorable aspects of the Series B convertible preferred include no maturity and ability to pay up to 50% of interest as PIK  Challenges include the high breakage cost, high conversion price and the inability to pay more than 62.5% as cash  As shown in the charts on the left, leverage likely remains elevated and implied share price remains low during the next few years  Share price remains low relative to both the $5 price, which allows PSP to convert, and the $8 price which allows Company to avoid breakage costs  Breakage costs reduce to $0 by 2025  Collective impact of these points is little to no need or benefit of refinancing the convertible preferred in the near term  In 2024-2025 onwards, as breakage costs reduce, a refinancing of the convertible preferred begins to make more sense  Considerations  ($ in millions)  High breakage costs preclude Company from refinancing convertible preferred in the near-term  C 
 

 Refinancing Considerations: Term Loan B  Company’s Term Loan B’s 2024 maturity creates risk of a going concern issue in Q4 2023 if not refinanced prior to then  To avoid this risk, Company should be prepared to refinance the Term Loan by Q1/Q2 2023 if not earlier  Tailwinds and headwinds for a TLB refinancing relative to the 2020 refinancing:  Refinancing in the private credit market would have some advantages relative to the TLB market (see next page)  Leveraged Finance Issuance (HY/LL/PC)  Source: S&P, LCD, LevFinInsights (LFI)  Notes: (1) Data as of 8/31/22   (2) Data as of 8/26/22    (3) Private credit data based on LFI and PWP estimate of LFI data’s market capture (41.5%)  Loan trading down in line with Index(1)  Monthly LevFIN Issuance by Type(2)(3)  Reduction in secured leverage from ~6x to ~4x  Greater runway if refinanced in next ~6 months  Continued growth and diversification of the business  Resolution of Decco patent infringement litigation  Convertible preferred weighs as a cash cost and is treated as debt by S&P  Volatility of current TLB market with loans pricing 100-125+ bps wider than existing trading  Small size of remaining TLB constrains liquidity   C 
 

 Private Credit  US HY Bonds   Term Loan B  Illustrative   Max Leverage  Highest leverage of any market  Highest leverage in broadly syndicated markets   Lowest leverage in broadly syndicated markets  Illustrative Maturity  Historically: 3 - 4 yearsMore recently: up to 7 years  Typically 5, 7, 8 years  7 years  Illustrative WACD  S+700 and up  9% and up  S+650 and up  Callability  Call protection generally through premiums vs. make whole  Make whole / Non-call period  Greatest callability in the market  Execution Risk  Low  Medium  Medium  Advantages & Considerations  Confidentiality  No public ratings requirement  Customized solution / partnership approach  Negotiated deal able to consider future vs. trailing performance  Will include financial covenants  Amortization and ECF sweeps  No financial maintenance covenants  No amortization or ECF sweep  Requires ratings  Minimize size (typically $300M)  Public marketing process  Callability  Often cov-lite  No amortization  Requires ratings and marketing  Minimize size (typically $300M)  Public marketing process  Comparing Private Credit to Broadly Syndicated Debt  C 
 

 Next Steps 
 

 Suggested Next Steps and Areas for Further Analysis  Further pressure test forecast sensitivities and levers  Develop an understanding of Company’s margin of safety over its commitments to investors (i.e., how much can Company “miss” its forecast by and still meet its debt amortization and preferred dividend payments?)  Refine “Market View” of projections  Adjust underlying assumptions to most accurately reflect the market’s likely perception of Company forecast  Continue to examine the implications of various external (macroeconomic, environmental, etc.) and internal (R&D, strategic investments, customer relationship development, etc.) factors on Company’s perceived ability to deliver on its objectives  Assess the impact delays in product development and regulatory approval could have on Company’s ability to capitalize on growth projects due to potential loss of first-mover advantage  Evaluate potential transaction with Paine Schwartz  Solidify standalone valuation prior to further engagement with Paine Schwartz  Evaluate different processes for engaging with Paine Schwartz  Decide on key points of contact among respective parties   Diligence on Dow’s position regarding potential sale process   Further diligence on the impact of refinancing the senior debt or preferred   Review of current capital structure  Consider refinancing scenarios for the Company’s senior debt and convertible preferred equity  Ideally, Company’s Term Loan B is refinanced by Q1 / Q2 2023 to avoid the risk of a “going concern” issue as the debt will become current in Q4 2023  The Company’s convertible preferred equity is treated as debt by S&P and has significant cash costs  1  2  3  4 
 

 Appendix 
 

 Annotated Stock Chart – Since January 2020  Source: Company Filings, Capital IQ as of 08/30/2022  Note: Fiscal year ends Dec. 31; EBITDA figures are non-GAAP 
 

 Current M&A Environment Overview and Outlook  M&A processes remain active and new launches continue, although at a slower pace; expect Strategic and Sponsor activity to pick up in H2’22 and accelerate into 2023, if financing markets stabilize  Strategics continue to pursue M&A, but many are digesting recent large-scale acquisitions; current environment is becoming advantageous for a select few  Sponsors have ample capital for new platforms, but increased financing costs have adversely impacted returns, limiting Sponsors’ ability to pay, benefitting Strategics   Public market and PF valuation receptivity to M&A have become increasingly sensitive to growth and value creation idiosyncrasies   Success in today’s market requires a compelling narrative with multiple value creation drivers 
 

 Chemicals M&A Volumes Since 2010 – North America and Western Europe ($100M – $3B)  Despite Market Volatility, 2022 Chemicals M&A Activity Continues and is On Track to be “Healthy”  Source: FactSet as of 08/30/2022  Notes: Represents Chemicals M&A volume from 01/01/2010 – 08/30/2022 for completed and pending transactions with a deal value between $100M and $3B and a North American or Western European target   (1) Represents annualized 2022 metric  ($ in billions)  Deal  Count  (1)  Median   2010 – 2021 Volume: $12B  (1) 
 

 Select Company Operational Benchmarking  CY2022E S&M, % of Revenue  CY2022E R&D, % of Revenue  CY2022E G&A, % of Revenue  Source: FactSet, S&P Capital IQ as of 08/30/22  Note: Metrics are based on calendar year financials. “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm  AgChem Tech  High Value Specialties  Food Safety / Security 
 

 Select Company Leverage Benchmarking  AgChem Tech  High Value Specialties  Food Safety / Security  Net debt / ltm ebitda  Gross debt / ltm ebitda  (1)  (1)  Source: FactSet, S&P Capital IQ as of 08/30/22  Notes: Metrics are based on calendar year financials; EV / Revenue multiples greater than 50.0x are considered “NM”. Negative multiples considered “NM”. “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm   (1) Adjustment bar considers $155M of convertible preferred equity included in debt 
 

 Select Company Credit Benchmarking  Interest coverage ratio  Cash as a % of market cap  Source: FactSet, S&P Capital IQ as of 08/30/22  Note: Metrics are based on calendar year financials; Interest coverage ratios with negative EBITDA are considered “NM.” “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm   (1) Includes Q2-22 LTM cash dividends paid for convertible preferred  OptimusPrime  FMC Corp  Scotts Miracle-Gro  American Vanguard  Bioceres  Novozymes  Croda  CHR Hansen  Balchem  Ecolab  Sotera  Diversey  Neogen  B-  BBB-  BB  -   -  -  -  -  -  A-  BB-  -  BB+  S&P Credit Ratings  AgChem Tech  High Value Specialties  Food Safety / Security  (1) 
 

 Discounted Cash Flow Analysis – Management Finance Case  ($ in millions)  (2)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (1)  Sources: Company financials  Notes: Assumes valuation date as of 9/30/2022; Assumes tax rate of 21.0%; Fiscal year ends Dec. 31   (1) 2022E-2026E amortization sourced from Q2-22 10Q estimated annual amortization schedule; 2027E-2032E amortization assumed to decrease by (0.5%) each year   (2) Change in NWC as a % of change in revenue held constant from 2027E 
 

 Discounted Cash Flow Analysis – Market Discount Case  Highly preliminary & confidential – Illustrative Analyses for Discussion  ($ in millions)  Excludes impact of Novel Antimicrobials and Novozymes Biologics from management projections and assumes 3% YoY growth for VitaFresh Botanicals Coatings and FreshCloud starting 2025E  Sources: Company financials  Notes: Assumes valuation date as of 9/30/2022; Assumes tax rate of 21.0%; Fiscal year ends Dec. 31   (1) Excludes impact of Novel Antimicrobials and Novozymes Biologics revenue and gross margin forecasts from management finance case and assumes 3% YoY growth for VitaFresh Botanicals Coatings and FreshCloud starting 2025E; OpEx, D&A, SBC, CapEx and change in NWC figures held constant from mgmt. finance case  (1) 
 

 Leveraged Buyout Analysis – Management Finance Case  transaction assumptions  Sources and uses  Irr / moic Sensitivity  Ability to Pay Sensitivity (Offer Price / Premium(1))  Illustrative transaction close: 12/31/2022  Offer price of $2.50 per share (61.3% premium)(1)  Implied EV: $588M(2)  Implied EV / LTM FY22E Revenue: 3.3x  Implied EV / LTM FY22E Adj. EBITDA: 8.8x  Minimum Operating Cash – $10M  Total Transaction Debt – $266M  4.0x Term Loan at 9.0% interest rate and 1.0% annual amortization  Exit – End of FY2027E (5-Year Hold)  Exit Value – $1.0B (9.0x LTM Adj. EBITDA)  Assumes 5% management incentive plan  Tax Rate – 21%; assumes zero taxes when EBT is negative  Excludes transaction expenses  Assumes balance sheet as of transaction close date   ($ in millions)  (3)  Sources: Company financials, FactSet, Capital IQ as of 08/30/22  Notes: (1) Premium to current share price of $1.55 as of 08/30/22   (2) Utilizes management cash and debt projections as of 12/31/22   (3) Represents change of control amount for Paine Schwartz Partners convertible preferred equity  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Leveraged Buyout Analysis – Management Finance Case (Cont’d)  ($ in millions)  Financial summary  CREDIT STATISTICS  Net Debt / LTM Adj. EBITDA  Sources: Company financials  Note: Fiscal year ends Dec. 31   (1) 2022E-2026E amortization sourced from Q2-22 10Q estimated annual amortization schedule; 2027E amortization assumed to grow by (0.5%)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1) 
 

 Illustrative WACC Analysis – Bloomberg  Source: Bloomberg, FactSet, Kroll, S&P Capital IQ as of 08/30/22  Notes: (1) 5-year weekly Bloomberg Beta   (2) Deloitte Corporate Tax Rates 2022   (3) Kroll’s supply-side long term equity risk premium   (4) 20-year treasury rate as of 08/30/22   (5) Size premium interpolated based on Kroll size premia by market cap range using assumed optimal capital structure for OptimusPrime of 80% Equity / Capitalization  ($ in millions) 
 

 Management Finance Case: Cash Flow Statement  Source: Company financials  ($ in millions) 
 

 Management Finance Case: COGS Drivers  Source: Company financials 
 

 OptimusPrime New Product Launch Assumptions  Source: Company materials 
 

 Legal Disclaimer  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service.  The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors.   Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction. 
 


Exhibit (c)(3)

 Discussion Materials  Project OptimusPrime  September 8, 2022 
 

 Table of Contents  Update to Management Plan and Valuation Perspectives  Key Considerations to Strategic Alternatives   Process Recommendations and Next Steps  Appendix 
 

 Update to Management Plan and Valuation Perspectives 
 

 Updates to Latest Management Long Range Plan   On September 3, 2022, management provided an updated financial model to PWP   The financial model was also shared with the Company’s debt advisor Rothschild & Co.  Overall, changes in the latest model were immaterial to the previous model received on August 25, 2022  After review, PWP notes the following:  No changes to the revenue forecasts. Management expects its diversification strategy continues to perform, with new growth products, particularly Harvista, Novel Antimicrobials (“BoB”) and Novozymes Biologics, to be major contributors to future revenues  In 2027E and beyond, the model now reflects R&D as a percentage of revenue at 6% vs. trending to 4%, previously. Management believes this revised assumption is more consistent with the Company’s innovation driven business model  Updated working capital assumptions based on current trends in the latest data, improving efficiencies in working capital and cash flow slightly  Updated “non-recurring expenses” line item which represents contingency cash outlays for litigation and M&A related expenses more in line with historical trends (immaterial change)  
 

 New vs. Previous Management Model Comparison  ($ in millions)  Revised OptimusPrime Management forecast contains minor EBITDA haircut and Cash Flow improvements  Source: Company financials  Revised forecast assumes greater efficiencies in DSO within NWC, therefore increasing cash flow and ending cash balance over time 
 

 Financial Overview – Historical & Management Finance Case  ($ in millions)  PWP Commentary  Company’s patent expiration of 1-MCP in 2014 resulted in revenue headwinds from 2016 onward  Gross profit margin expected to decline as management executes on its diversification efforts  The Company refinanced a portion of its long-term debt with convertible preferred stock through PSP in 2020   1  2  3  Source: Company financials 
 

 Total Revenue and Adj. EBITDA Margin over time  PWP Commentary  Long-Term Growth is Heavily Reliant on Success of New Growth Products   ($ in millions)  Projections are highly levered towards contribution from new growth projects, especially for EBITDA generation  New management team has thus far delivered on earnings more consistently than prior leadership  Market and potential buyers will heavily discount new growth products, due to ramp 5+ years away  Increasing competition from generics may erode SmartFresh Apple faster than expected  1  2  3  4  Source: Company financials   Notes: Financials per management finance case   (1) New Growth Products includes Novel Antimicrobials, Novozymes Biologics, VitaFresh Botanicals and Digital   (2) New Growth Products EBITDA includes product-level gross profit, Novozymes Opex and allocated Opex (excl. Novozymes), D&A and adjustments by percentage of revenue  Revenue Growth  5-Year CAGR   17A – 22E  5-Year CAGR   22E – 27E  10-Year CAGR   22E – 32E  Consolidated  1%  10%  11%  Core Products   6%  4%  New Growth Products(1)  89%  58%  (1)  Core Products  New Growth Products  Adj. EBITDA Margin  % of EBITDA from New Growth Products  (1)(2) 
 

 Updated Valuation Summary  Current Share Price: $1.69  Source: Company financials  Notes: Share price as of 09/06/2022   Comparable Companies multiple ranges derived by applying approximate difference in EV / EBITDA between AgroFresh and peers since Paine Schwartz’s preferred equity investment in 2020    (1) Broker price targets represent 12-month targets; prices discounted 12 months from date of publication to 09/06/2022; assumes cost of equity of 18.0%   (2) Reflects high end of WholeCo DCF valuation assuming management finance case, 3.0% perpetuity growth rate, and 15.0% WACC  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  Revisions to valuation reflect further thinking on preferred overhang and changes to methodology  $1.93  $2.57  $4.29  $3.83  New Products  Core  $0.86  $0.92  $1.48  $4.19(2) 
 

 Ability to Pay – 3 Year LBO  Traditional Sponsor – Potential Offer price / premium  Paine Schwartz Partners – Potential Offer price / premium  Commentary  Sources: Company financials, FactSet, Capital IQ as of 09/06/2022  Notes: (1) Premium to current share price of $1.69 as of 09/06/2022   (2) Utilizes management cash and debt projections as of 12/31/2022   (3) Represents change of control amount for Paine Schwartz Partners convertible preferred equity  Implied Potential Offer Price Per Share / Premium to Current Share Price  Required IRR  20.00%   21.25%   22.50%   23.75%   25.00%   Exit Multiple Adj. EBITDA  8.00x   $1.53 / (9.4%)  $1.39 / (18.0%)  $1.25 / (26.3%)  $1.11 / (34.2%)  $0.98 / (41.9%)  8.25x   $1.73 /   2.2%   $1.58 / (6.8%)  $1.43 / (15.4%)  $1.29 / (23.7%)  $1.16 / (31.6%)  8.50x   $1.92 / 13.8%   $1.77 /   4.4%   $1.61 / (4.5%)  $1.47 / (13.1%)  $1.33 / (21.4%)  8.75x   $2.12 / 25.4%   $1.95 / 15.7%   $1.80 /   6.4%   $1.65 / (2.6%)  $1.50 / (11.1%)  9.00x   $2.31 / 36.9%   $2.14 / 26.9%   $1.98 / 17.2%   $1.83 /   8.0%   $1.67 / (0.9%)  Implied Potential Offer Price Per Share / Premium to Current Share Price  Implied Offer Price Per Share / Premium to Current Share Price  Required IRR  Implied Offer Price Per Share / Premium to Current Share Price  Implied Offer Price Per Share / Premium to Current Share Price  20.00%   21.25%   22.50%   23.75%   25.00%   Exit Multiple Adj. EBITDA  8.00x   $2.77 / 63.7%   $2.62 / 55.1%   $2.48 / 46.8%   $2.35 / 38.8%   $2.22 / 31.2%   8.25x   $2.96 / 75.3%   $2.81 / 66.3%   $2.66 / 57.7%   $2.52 / 49.4%   $2.39 / 41.5%   8.50x   $3.16 / 86.9%   $3.00 / 77.5%   $2.85 / 68.6%   $2.70 / 60.0%   $2.56 / 51.7%   8.75x   $3.35 / 98.4%   $3.19 / 88.7%   $3.03 / 79.4%   $2.88 / 70.5%   $2.74 / 61.9%   9.00x   $3.55 / 110.0%   $3.38 / 100.0%   $3.22 / 90.3%   $3.06 / 81.1%   $2.91 / 72.2%   Highly preliminary & confidential – Illustrative Analyses for Discussion  Paine Schwartz Partners returns are more attractive compared to other traditional financial sponsors due to the lack of breakage costs  3-year LBO assumes exit in 2025E, resulting in less attractive returns vs. a longer hold period (launch and ramp of new products expected in 2026E and onward) 
 

 Ability to Pay – 5 Year LBO  Traditional Sponsor – Potential Offer price / premium  Paine Schwartz Partners – Potential Offer price / premium  Commentary  Sources: Company financials, FactSet, Capital IQ as of 09/06/2022  Notes: (1) Premium to current share price of $1.69 as of 09/06/2022   (2) Utilizes management cash and debt projections as of 12/31/2022   (3) Represents change of control amount for Paine Schwartz Partners convertible preferred equity  Implied Potential Offer Price Per Share / Premium to Current Share Price  Implied Offer Price Per Share   Required IRR  20.00%   21.25%   22.50%   23.75%   25.00%   Exit Multiple Adj. EBITDA  8.00x   $3.83 / 126.5%   $3.53 / 109.1%   $3.26 / 92.7%   $3.00 / 77.3%   $2.75 / 62.8%   8.25x   $4.02 / 137.8%   $3.71 / 119.8%   $3.43 / 102.9%   $3.16 / 87.0%   $2.91 / 72.0%   8.50x   $4.21 / 149.1%   $3.90 / 130.5%   $3.60 / 113.1%   $3.32 / 96.7%   $3.06 / 81.3%   8.75x   $4.40 / 160.4%   $4.08 / 141.3%   $3.77 / 123.3%   $3.49 / 106.4%   $3.22 / 90.5%   9.00x   $4.59 / 171.7%   $4.26 / 152.0%   $3.95 / 133.5%   $3.65 / 116.1%   $3.37 / 99.7%   Implied Potential Offer Price Per Share / Premium to Current Share Price  Implied Offer Price Per Share   Required IRR  20.00%   21.25%   22.50%   23.75%   25.00%   Exit Multiple Adj. EBITDA  8.00x   $2.59 / 53.4%   $2.30 / 36.0%   $2.02 / 19.6%   $1.76 /   4.2%   $1.52 / (10.3%)  8.25x   $2.78 / 64.7%   $2.48 / 46.7%   $2.19 / 29.8%   $1.93 / 13.9%   $1.67 / (1.0%)  8.50x   $2.97 / 76.0%   $2.66 / 57.4%   $2.37 / 40.0%   $2.09 / 23.6%   $1.83 /   8.2%   8.75x   $3.17 / 87.3%   $2.84 / 68.2%   $2.54 / 50.2%   $2.25 / 33.3%   $1.98 / 17.4%   9.00x   $3.36 / 98.6%   $3.02 / 78.9%   $2.71 / 60.4%   $2.42 / 43.0%   $2.14 / 26.6%   Similarly, Paine Schwartz is able to offer a superior premium vs. other financial sponsors given the lack of breakage costs   Assuming a 22.5% IRR requirement and a 8.5x exit, Paine Schwartz is able to offer $1.23 per share in superior value   Estimated breakage costs of ~$81M as of 12/31/2022   5-year LBO assumes exit in 2027E, resulting in more attractive returns vs. a 3-year LBO given ramp up of new products   Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Potential Strategic Buyers  Sources: Company filings, Moody’s, FactSet, Capital IQ as of 09/06/2022  EV / 2022E EBITDA: 9.5x   Cash: $22M  EV / 2022E EBITDA: N/A  Cash: N/A  EV / 2022E EBITDA: 21.7x   Cash: $76M  EV / 2022E EBITDA: 12.3x  Cash: $73M  EV / 2022E EBITDA: 14.1x   Cash: $254M  EV / 2022E EBITDA: 16.3x   Cash: $904M  EV / 2022E EBITDA: 15.2x   Cash: $792M  EV / 2022E EBITDA: 7.5x  Cash: $456M  EV / 2022E EBITDA: 19.8x   Cash: $125M  EV / 2022E EBITDA: 12.0x  Cash: $592M  EV / 2022E EBITDA: N/A  Cash: N/A  EV / 2022E EBITDA: 13.1x  Cash: $68M   EV / 2022E EBITDA: 7.8x  Cash: $131M  EV / 2022E EBITDA: 5.8x  Cash: $8,412M   EV / 2022E EBITDA: 10.5x  Cash: $45M  EV / 2022E EBITDA: 15.8x  Cash: $202M  EV / 2022E EBITDA: 4.5x   Cash: $5,063M  EV / 2022E EBITDA: 7.5x  Cash: $687M 
 

 Precedent Premia Analysis  Analysis for U.S. companies acquired since September 2020 indicates targets receiving higher premia the steeper the discount to 52-week high  Highly preliminary & confidential – Illustrative Analyses for Discussion  Source: FactSet as of 09/06/2022  Notes: Unaffected premiums shown for acquisitions since 09/06/2022 with a transaction value between $100M – $3B and targets in the United States; excludes MOEs and transactions with targets industries of Energy, Insurance, Mining, Oil & Gas, REITs, Railroads, and Utilities   The Company is currently trading at 64% of its 52W High   (1) % of 52W High reflects share price as of unaffected date divided by 52W High as of unaffected date    (2) Reflects acquisitions where the target was acquired at a greater than 100% premium to its share price as of unaffected date 
 

 7.0x Assumed Multiple  9.0x Assumed Multiple  Discounted Future Share Price Sensitivity(1)  PWP Commentary  Present Value of Future Share Price  Inability to achieve management projections, particularly in the next 2 years, will result in a material impact to Adj. EBITDA and share price  Given the Company’s current capital structure, the discounted future share price is highly sensitive to any potential setbacks in plan   1  2  Source: Company financials   Notes: Revenue miss haircuts management finance case total revenue from 2023E to 2027E, holds gross margin (%) and OpEx costs ($) constant versus management case   (1) Assumes valuation date of 12/31/2022; uses current FDSO, NCI, market capitalization and EV; assumes cost of equity of 18.0%. Convertible Preferred taken at face value in status quo scenario (i.e., no breakage costs included)  Adjusted EBITDA Margin  Mgmt. Finance Case  38%  37%  36%  36%  37%  39%  10% Revenue Miss  38%  33%  32%  33%  34%  36%  10% Revenue Miss  Mgmt. Finance Case 
 

 Analysis at Various Share Prices  Source: FactSet, Capital IQ, Company Filings, Company financials  Notes: (1) Represents change of control amount for Paine Schwartz Partners convertible preferred equity   (2) Multiples in AVP reflect convertible preferred at liquidation preference, assuming 2.0X MOIC  ($ in millions, except share price)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (2)  (2) 
 

 Key Considerations to Strategic Alternatives 
 

 Potential Sale Process Considerations  Management long-range plan   Senior debt refinancing timing and process  Convertible preferred breakage costs over time   Optimus valuation  Sale process considerations   Positioning with Dow  A  B  C  D  E  F 
 

 Scheduled Principal repayments and amortization  2024E Term Loan Maturity Needs to be Addressed by Early 2023  Source: Company Filings, FactSet  Notes: (1) Represents remaining principal in 2022 as of Q2-22A   (2) Figures from management model; excludes convertible preferred stock   (3) Interest includes cash interest and cash dividend payments on convertible preferred stock from management model  Moody’s Credit Rating: B3  S&P Credit Rating: B-  (1)  (2)  (2)  (3)  Based on Updated OpEx Assumptions, Company Has Room to Miss Projections While Maintaining the Ability to service Debt  Revenue Haircut (2023E – 2027E)  No Haircut  10%   21%   30%   2027E Revenue   $287   $258   $228   $201   2027E EBITDA   113   94   74   56   2027E Ending Cash Balance   127   70   10   (43)  Assumes ending 2022 cash balance of ~$62M  Haircuts management case total revenue from 2023E to 2027E  Gross margin held constant  OPEX $ costs remain unchanged vs. management case (assuming Company unable to capitalize on investments to grow the top-line)  Company can miss management projections by up to ~20% and maintain the ability to service debt  PWP Assessment  Upcoming term loan maturity in 2024 needs to be addressed by early 2023 before the Company’s Going Concern status comes into question in Q4 2023 
 

 Refinancing Considerations: Term Loan B  Company’s Term Loan B’s 2024 maturity creates risk of a going concern issue in Q4 2023 if not refinanced prior to then  To avoid this risk, Company should be prepared to refinance the Term Loan by Q1/Q2 2023, if not earlier  Tailwinds and headwinds for a TLB refinancing relative to the 2020 refinancing:  Refinancing in the private credit market would have some advantages relative to the TLB market  Leveraged Finance Issuance (HY/LL/PC)  Source: S&P, LCD, LevFinInsights (LFI)  Notes: (1) Data as of 09/06/2022   (2) Data as of 08/31/2022, private credit data based on LFI and PWP estimate of LFI data’s market capture (41.5%)  Loan trading down in line with Index(1)  Monthly LevFIN Issuance by Type ($B)(2)  Reduction in secured leverage from ~6x to ~4x  Greater runway if refinanced in next ~6 months  Continued growth and diversification of the business  Resolution of Decco patent infringement litigation  Convertible preferred weighs as a cash cost and is treated as debt by S&P  Volatility of current TLB market with loans pricing 100-125+ bps wider than existing trading  Small size of remaining TLB constrains liquidity  
 

 commentary  Convertible Preferred Accretes Over Time Through PIK Interest  Dividend Rates  16% per annum, of which 50% is payable in cash and 50% is payable in kind for the first year after the closing date, after which 50% will be payable in cash, 37.5% will be payable in kind and 12.5% will be payable in cash or in kind at the company’s discretion (management model assumes 50% cash and 50% PIK in forecast period)  PSP has the right to appoint an additional member to the Board commensurate with their as-converted ownership stake   If PSP has over 50% of Directors on the Board and Dow owns at least 20% of AgroFresh’s as-converted common stock, Dow has the right to designate an additional member to the Board  There is also one share of Series A Preferred Stock owned by Dow, entitling Dow to appoint one director to the Board   Source: Company Filings  Notes: (1) Assumes preferred stock is converted at a conversion price of $5.00 and the amount of shares outstanding remains constant from Q2-22A   (2) Reflects the average for the year, with a 10% cash dividend rate for Q3 2021, Q4 2021 and Q1 2022  ($ in millions)  In a status quo scenario, Paine Schwartz’s ownership, on an as-converted basis, is expected to cross 50% by Q1 2028  (1)  (2)  (2) 
 

 High Breakage Costs Associated with Near-term Series B Refinancing  Source: Company financials  Note: (1) Based on 56.3M diluted shares outstanding; Future Share Prices are not discounted to present  Growth of Equity Value Over time @7.0x EV / EBITDA  Implied Future Share Price(1)  Net Debt  Convert. Pref.  Equity  ($ in millions)  Convertible preferred continues to dilute to common shareholders over time 
 

 Process Recommendations and Next Steps 
 

 Key Process Alternatives   Perform market check with select strategics and sponsors to drive competitive tension  Execute NDAs and prepare for typical sell-side process timeline  Solicitation of other potential buyers through “go-shop” provision in merger agreement  Launch Term Loan B refinancing process in the near-term   Expect to refinance Series B Convertible Preferred in 2024 / 2025 when breakage costs are reduced  Engage with PSP on   Potential Offer  Discussion with other Potential Acquirors  Status Quo 
 

 Peter Sykes  Director  Joined the AgroFresh Board of Directors in June 2022  Principal of Church Lane Advisory, an advisory and strategic investing firm  Served over 20 years at Dow, retiring in July 2021  Most recently served as Vice President of Mergers & Acquisitions  Replaced Torsten Kraef, the Senior Vice President of Corporate Development for Dow  Dow Considerations and Positioning   New Board member biography  Dow ownership (on an as-converted basis)(1)   Dow owns nearly 40% of the Company’s common stock (~25% post-conversion of Series B), giving it a strong influence on the outcome of any vote  New Dow representative, Peter Sykes, joined the Board in June 2022  Retired from Dow in July 2021  Given spin-off in 2015, it is unlikely that Dow sees Company as an ongoing strategic investment  Determine best way to inform Dow of strategic thinking – communicate through Peter or directly with Dow?   Assess Dow’s return threshold  Q4 2022E  Source: Company Filings  Note: (1) Assumes preferred stock is converted at a conversion price of $5.00 and the amount of shares outstanding remains constant from Q2-22A 
 

 Appendix 
 

 Public Market Data & Analysis  
 

 Ev / NTM EBITDA – Since January 2019  Historical Valuation Multiples  Source: FactSet as of 09/06/2022  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen  Company has historically traded at ~7.0x EV / NTM EBITDA since January 2019 
 

 SmartFresh Apple revenue anticipated to erode over time due to pricing pressures from generics entering the market   Antimicrobials projected to be a large contributor to revenue, primarily driven by anticipated Novel Antimicrobial and Novozymes Biologics product launches in 2026  Total gross margin percentage forecasted to decline as Company diversifies into lower margin products  R&D and S&M as a % of revenue decline modestly through 2026E and are largely held flat thereafter; operating leverage seen mainly from G&A efficiencies  Management Finance Case: P&L  Source: Company financials  ($ in millions)  PWP commentary  1  2  3  4  1  2  3  4 
 

 Management Finance Case: Revenue and Gross Margin Detail  Source: Company financials  1  1  2  Novel Antimicrobials and Novozymes Biologics contribute a large amount to growth and revenue in the outyears  Diversification growth products have significantly lower margins than legacy SmartFresh Apple  PWP commentary  1  2 
 

 Management Finance Case: Cash Flow Statement  Source: Company financials  ($ in millions) 
 

 Limited estimates available 2024E+; only 1 broker available  P&L Comparison: Consensus Estimates vs. Management Finance Case  Source: FactSet, Capital IQ, Company Filings, Company financials  Notes: (1) Broker estimates as of 09/06/2022   (2) Represents Finance case in management projections received on 08/25/2022  ($ in millions)  Near-term management projections are in-line with consensus estimates. Difficult to compare 2024E+ projections due to lack of broker estimates 
 

 Public Comparable Companies Analysis  Source: S&P Capital IQ and FactSet as of 09/06/2022, company financials  Notes: Metrics are based on calendar year financials; EV / Revenue, EV / EBITDA, and P / E multiples greater than 50.0x, 75.0x, and 100.0x   respectively are considered “NM”. Negative multiples are considered “NM”. “NA” indicates that a value was not available  ($ in millions, except per share values)  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Select Company Valuation Benchmarking  CY2023E EV / EBITDA  Source: FactSet, S&P Capital IQ as of 09/06/2022  Notes: Metrics are based on calendar year financials; EV / Revenue multiples greater than 50.0x are considered “NM”. Negative multiples considered “NM”. “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm   (1) FCF yield calculated as CFO less CapEx divided by Market Capitalization   (2) Assumes preferred dividend payment of $14.3M per Management Case  AgChem Tech  High Value Specialties  Food Safety / Security  CY2023E FCF Yield(1)  AgChem Tech  High Value Specialties  Food Safety / Security  5%  FCF Yield including 2023E Debt Repayment and Preferred Dividend Payment(2) 
 

 Select Company Operational Benchmarking  CY2022E Ebitda margin  Source: FactSet, S&P Capital IQ as of 09/06/2022  Notes: Metrics are based on calendar year financials; Debt / LTM EBITDA and Net Debt / LTM EBITDA multiples with negative EBITDA are considered “NM.” “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm     CY2021A – CY2023E Revenue CAGR  CY2022E Gross margin  AgChem Tech  High Value Specialties  Food Safety / Security 
 

 Select Precedent Transactions  Source: Company filings, Moody’s, press releases  Notes: (1) Reflects forward multiple due to data availability   (2) Assumes 25% EBITDA Margin per JBT Investor Presentation  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (1)  (1)  (2)  (1)  (1) 
 

 Present Value of Future Share Price (Status Quo w/ No Breakage Costs)  Source: Company financials  Notes: Assumes valuation date of 12/31/2022; uses current FDSO, NCI, market capitalization and EV; assumes cost of equity of 18.0%. Convertible Preferred    taken at face value in status quo scenario (i.e., no breakage costs included)  Significant common shareholder dilution and impact in the near term from the convertible preferred  Highly preliminary & confidential – Illustrative Analyses for Discussion  ($ in millions) 
 

 Leveraged Buyout Analysis – Management Finance Case  Illustrative transaction close: 12/31/2022  Offer price of $2.75 per share (62.7% premium)(1)  Implied EV: $600M(2)  Implied EV / LTM FY22E Revenue: 3.4x  Implied EV / LTM FY22E Adj. EBITDA: 9.0x  Minimum Operating Cash – $10M  Total Transaction Debt – $266M  4.0x Term Loan at 9.0% interest rate and 1.0% annual amortization  Exit – End of FY2027E (5-Year Hold)  Exit Value – $1.0B (9.0x LTM Adj. EBITDA)  Assumes 5% management incentive plan  Tax Rate – 21%; assumes zero taxes when EBT is negative  Excludes transaction expenses  Assumes balance sheet as of transaction close date   IRR / MOIC Sensitivity  Ability to Pay Sensitivity (Offer Price / Premium(1))  Transaction Assumptions  Sources & Uses  ($ in millions)  (3)  Sources: Company financials, FactSet, Capital IQ as of 09/06/2022  Notes: (1) Premium to current share price of $1.69 as of 09/06/2022   (2) Utilizes management cash and debt projections as of 12/31/2022   (3) Represents change of control amount for Paine Schwartz Partners convertible preferred equity  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Financial Summary  Credit Statistics  Leveraged Buyout Analysis – Management Finance Case (Cont’d)  ($ in millions)  Net Debt / LTM Adj. EBITDA  Sources: Company financials  Notes: Fiscal year ends Dec. 31   (1) 2022E-2026E amortization sourced from Q2-22 10Q estimated annual amortization schedule; 2027E amortization assumed to grow by (0.5%)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1) 
 

 Illustrative WACC Analysis – Bloomberg  Source: Bloomberg, FactSet, Kroll, S&P Capital IQ as of 09/06/2022  Notes: (1) 5-year weekly Bloomberg Beta   (2) Deloitte Corporate Tax Rates 2022   (3) Kroll’s supply-side long term equity risk premium   (4) 20-year treasury rate as of 09/06/2022   (5) Size premium interpolated based on Kroll size premia by market cap range using assumed optimal capital structure for OptimusPrime of 80% Equity / Capitalization  ($ in millions) 
 

 Legal Disclaimer  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service.  The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors.   Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction. 
 


Exhibit (c)(4)

 Discussion Materials  Project OptimusPrime  September 19, 2022 
 

 Financial Overview – Historical & Management Finance Case  ($ in millions)  Source: Company financials 
 

 New Growth Products  Total Revenue and Adj. EBITDA Margin over time  Long-Term Growth is Heavily Reliant on Success of New Growth Products   ($ in millions)  Source: Company financials   Notes: Financials per management finance case   (1) Core Products includes SmartFresh Apple, SmartFresh Diversification, Harvista, Ornamentals, Landspring, Conventional Fungicides, Disinfectants, Coatings (Teycer Originals) and Control Tec; (2) New Growth Products includes Novel Antimicrobials, Novozymes Biologics, VitaFresh Botanicals and Digital; (3) New Growth Products EBITDA includes product-level gross profit, Novozymes Opex and allocated Opex (excl. Novozymes), D&A and adjustments by percentage of revenue  Revenue Growth  5-Year CAGR   17A – 22E  5-Year CAGR   22E – 27E  10-Year CAGR   22E – 32E  Consolidated  1%  10%  11%  Core Products(1)  6%  4%  New Growth Products(2)  89%  58%  (2)  Core Products  Adj. EBITDA Margin  % of EBITDA from New Growth Products  (2)(3) 
 

 Limited estimates available 2024E+; only 1 broker available  P&L Comparison: Consensus Estimates vs. Management Finance Case  Source: FactSet, Capital IQ, Company Filings, Company financials  Notes: (1) Broker estimates as of 09/16/2022  ($ in millions) 
 

 Ev / NTM EBITDA – Since January 2019  Historical Valuation Multiples  Source: FactSet as of 09/16/2022  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen  OptimusPrime EV / NTM EBITDA High Since 01/19: 9.2x     OptimusPrime EV / NTM EBITDA Low Since 01/19: 6.7x 
 

 Relative Stock Price Performance vs. Peers  Source: Capital IQ as of 09/16/22  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen   (1) Reflects performance since 06/18/2018   (1)  Share Price performance indexed to Company Since January 2019 
 

 Select Company Operational Benchmarking  CY2022E Ebitda margin  Source: FactSet, S&P Capital IQ as of 09/16/2022  Notes: Metrics are based on calendar year financials; Debt / LTM EBITDA and Net Debt / LTM EBITDA multiples with negative EBITDA are considered “NM.” “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm     CY2021A – CY2023E Revenue CAGR  CY2022E Gross margin  AgChem Tech  High Value Specialties  Food Safety / Security 
 

 7.0x Assumed Multiple  9.0x Assumed Multiple  Discounted Future Share Price Sensitivity(1)  Present Value of Future Share Price (Status Quo w/ No Breakage Costs)  Source: Company financials   Notes: Revenue miss haircuts management finance case total revenue from 2023E to 2027E, holds gross margin (%) and OpEx costs ($) constant versus management case   (1) Assumes valuation date of 12/31/2022; uses current FDSO, NCI, market capitalization and EV; assumes cost of equity of 18.0%. Convertible Preferred taken at face value in status quo scenario (i.e., no breakage costs included)  Adjusted EBITDA Margin  Mgmt. Finance Case  38%  37%  36%  36%  37%  39%  10% Revenue Miss  38%  33%  32%  33%  34%  36%  10% Revenue Miss  Mgmt. Finance Case  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Discounted Cash Flow Analysis – Segmented by Product  DCF analysis conducted on a product basis, split between Core Products and New Products, due to key differences in growth and risk attributed to the two different types of businesses  Sources: Company financials  Notes: Assumes valuation date as of 9/30/2022; Assumes tax rate of 21.0%; Fiscal year ends Dec. 31;    New Products includes Novel Antimicrobials, Novozymes Biologics, VitaFresh Botanicals and Digital; Core Products includes SmartFresh Apple, SmartFresh Diversification, Harvista, Ornamentals, Landspring, Conventional Fungicides, Disinfectants, Coatings (Teycer Originals) and Control Tec; COGS allocated by product line; Operating expenditures allocated as a percentage of 1 year forward sales contribution; D&A and other adjustments allocated as a percentage of in year sales contribution   (1) Net debt includes convertible preferred at liquidation preference including breakage costs, assuming 2.0X MOIC  Core Products  10 Year DCF  Perp. Growth Rate: 0% - 2%  WACC: 14% - 16%  New Products  10 Year DCF  Perp. Growth Rate: 2% - 4%  WACC: 16% - 18%  Combined Core & New Products  Combines values derived from Core & New Products DCFs  Highly preliminary & confidential – Illustrative Analyses for Discussion  Implied Value per Share(1)  Key Assumptions 
 

 Analysis at Various Share Prices  Source: FactSet, Capital IQ, Company Filings, Company financials  Notes: (1) Represents change of control amount for Paine Schwartz Partners convertible preferred equity   (2) Multiples in AVP reflect convertible preferred at liquidation preference, assuming 2.0X MOIC  ($ in millions, except share price)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (2)  (2) 
 

 Public Comparable Companies Analysis  Source: S&P Capital IQ and FactSet as of 09/16/2022, company financials  Notes: Metrics are based on calendar year financials; EV / Revenue, EV / EBITDA, and P / E multiples greater than 50.0x, 75.0x, and 100.0x   respectively are considered “NM”. Negative multiples are considered “NM”. “NA” indicates that a value was not available  ($ in millions, except per share values) 
 

 Legal Disclaimer  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service.  The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors.   Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction. 
 


Exhibit (c)(5)

 Discussion Materials  Project OptimusPrime  October 18, 2022 
 

 New vs. Previous Management Finance Case Comparison  ($ in millions)  Revised OptimusPrime Management Finance Case includes August 2022 results and FX-related updates for 2022F+  Source: Company financials 
 

 Financial Overview – Historical & Updated Management Finance Case (10/12/2022)  ($ in millions)  Source: Company financials 
 

 New Growth Products  Total Revenue and Adj. EBITDA Margin over time  Long-Term Growth is Heavily Reliant on Success of New Growth Products   ($ in millions)  Source: Company financials   Notes: Financials per management finance case   (1) Core Products includes SmartFresh Apple, SmartFresh Diversification, Harvista, Ornamentals, Landspring, Conventional Fungicides, Disinfectants, Coatings (Teycer Originals) and Control Tec; (2) New Growth Products includes Novel Antimicrobials, Novozymes Biologics, VitaFresh Botanicals and Digital; (3) New Growth Products EBITDA includes product-level gross profit, Novozymes Opex and allocated Opex (excl. Novozymes), D&A and adjustments by percentage of revenue  Revenue Growth  5-Year CAGR   17A – 22E  5-Year CAGR   22E – 27E  10-Year CAGR   22E – 32E  Consolidated  Current (10/12)  0%  11%  11%  Prior (09/03)  1%  10%  11%  Core Products(1)  Current (10/12)  7%  5%  Prior (09/03)  6%  4%  New Growth Products(2)  Current (10/12)  91%  59%  Prior (09/03)  89%  58%  (2)  Core Products  Adj. EBITDA Margin  % of EBITDA from New Growth Products  (2)(3)  Prior case (09/03) revenue and Adj. EBITDA margin  $176  38%  $186  37%  $199  36%  (1) 
 

 Updated Valuation Summary  Current Share   Price: $1.60  Source: Company financials  Notes: Share price as of 10/10/2022   Comparable Companies multiple ranges derived by applying approximate difference in EV / EBITDA between AgroFresh and peers since Paine Schwartz’s preferred equity investment in 2020; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 67.5% cash / 32.5% PIK split) based on management assumptions   (1) Broker price targets represent 12-month targets; prices discounted 12 months from date of publication to 10/10/2022; assumes cost of equity of 18.0%  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  Valuation update based on revised management projections received 10/12/2022  $1.96  $2.61  $4.35  $3.89  10/10 Offer   Price: $2.85  $0.03  NM  Convertible Preferred valued at 2.0x MOIC for all enterprise value-based valuation methodologies 
 

 Paine Schwartz Partners LBO (returns Inclusive of Original Convertible Preferred Investment)  Traditional Sponsor LBO(1)  5 Year LBO – Paine Schwartz Partners vs. Traditional SponsorAssumes Offer Price of $2.85 per Share and 8.5x Exit Multiple  ($ in millions)  Sources: Company financials  Notes: Utilizes management cash and debt projections as of 12/31/2022; financials per management finance case   (1) Includes estimated breakage costs of ~$81M as of 12/31/2022   Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Illustrative PSP Returns  Components of Paine Schwartz Partners Illustrative Returns  Sources: Company financials, FactSet, Capital IQ as of 10/10/2022  Notes: Financials per management finance case   (1) Includes OID   (2) 16% total interest rate on Convertible Preferred, broken out by 8% cash dividend / 8% PIK, 9% cash dividend / 7% PIK and 8% cash dividend / 8% PIK for FY2020, FY2021, and FY2022, respectively   (3) Reflects 8.5x EV / EBITDA exit multiple  FY 2020  FY 2021  FY 2022  FY 2027  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  2027E  Initial Pref. Investment(1)  ($147.8)  Cash Preferred Dividends(2)  $2.2  $3.0  $3.0  $3.1  $3.9  $4.0  $4.0  $3.3  $3.3  $3.4  LBO Purchase Equity  ($124.8)  LBO Exit Equity(3)   $882.2   IRR /   MOIC  20.0% /   3.2x  ($ in millions)  PSP incremental investment required for take-private (assuming $2.85 offer price and 4.0x PF leverage); assumes no debt refinancing  Irr / moic Sensitivity  Key Commentary   PSP will have earned a ~16% IRR on its Convertible Preferred investment alone, assuming exit at 2022 year-end  PSP’s total IRR (factoring in original Convertible Preferred investment) is slightly lower than the standalone LBO IRR given the lower returns of the convertible preferred  Highly preliminary & confidential – Illustrative Analyses for Discussion  Returns based on initial Convertible Preferred investment plus subsequent 5-year LBO 
 

 7.0x Assumed Multiple  9.0x Assumed Multiple  Discounted Future Share Price Sensitivity(1)  Present Value of Future Share Price (Status Quo w/ No Breakage Costs)Convertible Preferred Valued at Face Value  Source: Company financials   Notes: Revenue miss haircuts management finance case total revenue from 2023E to 2027E, holds gross margin (%) and OpEx costs ($) constant versus management case; assumes existing debt is refinanced in the same amount at its maturity in 2024   (1) Assumes valuation date of 12/31/2022; uses current FDSO, NCI, market capitalization and EV; assumes cost of equity of 18.0%; Convertible Preferred taken at face value in status quo scenario (i.e., no breakage costs included)  Adjusted EBITDA Margin  Mgmt. Finance Case  37%  36%  35%  36%  37%  39%  10% Revenue Miss  37%  32%  32%  33%  34%  36%  10% Revenue Miss  Mgmt. Finance Case  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 High Breakage Costs Associated with Near-term Series B Refinancing  Source: Company financials  Notes: Assumes existing debt is refinanced in the same amount at its maturity in 2024   (1) Based on 56.3M diluted shares outstanding; Future Share Prices are not discounted to present  Growth of Equity Value Over time @ 7.0x EV / EBITDA  Implied Future Share Price(1)  Net Debt  Convert. Pref.  Equity  ($ in millions)  Convertible preferred continues to dilute to common shareholders over time  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Analysis at Various Share Prices  Source: FactSet and Capital IQ as of 10/10/2022, Company filings, Company financials  Notes: (1) Represents change of control amount for Paine Schwartz Partners convertible preferred equity; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 67.5% cash / 32.5% PIK split) based on management assumptions   (2) Multiples in AVP reflect convertible preferred at liquidation preference, assuming 2.0X MOIC  ($ in millions, except share price)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (2)  (2) 
 

 Potential Private Equity and Strategic Buyers  Observations On Market environment and current trends  Focus on reduction of food waste / conservation of resources  Changing dietary trends towards fresh fruit and produce  Increasing supply chain risks and disruptions  Increasing demand for data in terms of traceability, quality and food safety   Strategics  Potential buyers  Sponsors 
 

 Appendix 
 

 commentary  Convertible Preferred Accretes Over Time Through PIK Interest  Dividend Rates  16% per annum, of which 50% is payable in cash and 50% is payable in kind for the first year after the closing date, after which 50% will be payable in cash, 37.5% will be payable in kind and 12.5% will be payable in cash or in kind at the company’s discretion (management model assumes 50% cash and 50% PIK in forecast period)  PSP has the right to appoint an additional member to the Board commensurate with their as-converted ownership stake   If PSP has over 50% of Directors on the Board and Dow owns at least 20% of AgroFresh’s as-converted common stock, Dow has the right to designate an additional member to the Board  There is also one share of Series A Preferred Stock owned by Dow, entitling Dow to appoint one director to the Board   Source: Company filings  Notes: (1) Assumes preferred stock is converted at a conversion price of $5.00 and the amount of shares outstanding remains constant from Q2 2022   (2) Reflects the average for the year, with a 10% cash dividend rate for Q3 2021, Q4 2021 and Q1 2022  ($ in millions)  In a status quo scenario, Paine Schwartz’s ownership, on an as-converted basis, is expected to cross 50% by Q1 2028  (1)  (2)  (2)  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Precedent Premia Analysis  Analysis for U.S. companies acquired since October 2020 indicates targets receiving higher premia the steeper the discount to 52-week high  Highly preliminary & confidential – Illustrative Analyses for Discussion  Source: FactSet as of 10/10/2022  Notes: Unaffected premiums shown for acquisitions since 10/10/2020 with a transaction value between $100M – $3B and targets in the United States; excludes MOEs and transactions with targets industries of Energy, Insurance, Mining, Oil & Gas, REITs, Railroads, and Utilities   The Company is currently trading at 69% of its 52W High   (1) % of 52W High reflects share price as of unaffected date divided by 52W High as of unaffected date    (2) Reflects acquisitions where the target was acquired at a greater than 100% premium to its share price as of unaffected date 
 

 Limited estimates available 2024E+; only 1 broker available  P&L Comparison: Consensus Estimates vs. Management Finance Case  Source: FactSet and Capital IQ as of 10/10/2022, Company filings, Company financials  Notes: (1) Broker estimates as of 10/10/2022  ($ in millions) 
 

 Ev / NTM EBITDA – Since January 2019  Historical Valuation Multiples  Source: FactSet as of 10/10/2022  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen  OptimusPrime EV / NTM EBITDA High Since Jan-19: 9.2x     OptimusPrime EV / NTM EBITDA Low Since Jan-19: 6.7x 
 

 Relative Stock Price Performance vs. Peers  Source: Capital IQ as of 10/10/2022  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen   (1) Reflects performance since 06/18/2018   (1)  Share Price performance indexed to Company Since January 2019 
 

 Public Comparable Companies Analysis  Source: FactSet and Capital IQ as of 10/10/2022, company financials  Notes: Metrics are based on calendar year financials; EV / Revenue, EV / EBITDA, and P / E multiples greater than 50.0x, 75.0x, and 100.0x   respectively are considered “NM”. Negative multiples are considered “NM”. “NA” indicates that a value was not available  ($ in millions, except per share values) 
 

 Select Comparable Companies Operational Benchmarking  CY2022E Ebitda margin  Source: FactSet and Capital IQ as of 10/10/2022  Notes: Metrics are based on calendar year financials; Debt / LTM EBITDA and Net Debt / LTM EBITDA multiples with negative EBITDA are considered “NM.” “NA” indicates that a value was not available; Large AgChem includes Bayer, Nutrien, Corteva, BASF, Dow, CF Industries, Mosaic, FMC Corp, UPL Limited, and Nufarm     CY2021A – CY2023E Revenue CAGR  CY2022E Gross margin  AgChem Tech  High Value Specialties  Food Safety / Security 
 

 Select Precedent Transactions  Source: Company filings, Moody’s, press releases  Notes: (1) Reflects forward multiple due to data availability   (2) Assumes 25% EBITDA Margin per JBT Investor Presentation  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1)  (1)  (1)  (2)  (1)  (1) 
 

 Leveraged Buyout Analysis – 5 Year Illustrative PSP Returns (No Breakage Costs)  transaction assumptions  Sources and uses  Irr / moic Sensitivity  Ability to Pay Sensitivity (Offer Price / Premium(1))  Illustrative transaction close: 12/31/2022  Offer price of $2.85 per share (78.1% premium)(1)  Implied EV: $544M(2)  Implied EV / LTM FY22E Revenue: 3.3x  Implied EV / LTM FY22E Adj. EBITDA: 8.8x  Minimum Operating Cash – $10M  Total Transaction Debt – $248M  4.0x Term Loan at 9.0% interest rate and 1.0% annual amortization  Exit – End of FY2027E (5-Year Hold)  Exit Value – $959M (8.5x LTM Adj. EBITDA)  Assumes 5% management incentive plan  Tax Rate – 21%; assumes zero taxes when EBT is negative  Excludes transaction expenses  Assumes balance sheet from management projections as of 12/31/2022  ($ in millions)  (3)  Sources: Company financials, FactSet and Capital IQ as of 10/10/2022  Notes: Financials per management finance case   (1) Premium to current share price of $1.60 as of 10/10/2022   (2) Utilizes management cash, debt and convertible preferred equity projections as of 12/31/2022   (3) Represents management projections as of 12/31/2022  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Leveraged Buyout Analysis – 5 Year Illustrative PSP Returns (No Breakage Costs) (Cont’d)  ($ in millions)  Financial summary  CREDIT STATISTICS  Net Debt / LTM Adj. EBITDA  Sources: Company financials  Note: Fiscal year ends Dec. 31; Financials per management finance case   (1) 2022E-2026E amortization sourced from Q2 2022 10-Q estimated annual amortization schedule; 2027E amortization assumed to grow by (0.5%)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (1) 
 

 Discounted Cash Flow Analysis – Management Finance Case  New Products Unlevered Free Cash Flows  Core Unlevered Free Cash Flows  Combined Terminal Value Build and Valuation  ($ in millions)  Sources: Company financials, FactSet as of 10/10/2022  Notes: Assumes valuation date as of 09/30/2022; assumes tax rate of 21.0%; fiscal year ends Dec. 31; WACCs of 15.0% and 17.0% utilized for Core and New Products respectively; perpetuity growth rates of 1.0% and 3.0% utilized for Core and New Products, respectively; D&A, SBC, and change in NWC allocated based on in-year sales contribution; CapEx allocated based on forward year sales contribution (excl. 2032E)   (1) 2022E-2026E amortization sourced from Q2 2022 10-Q estimated annual amortization schedule; 2027E-2032E amortization assumed to decrease by (0.5%) each year   (2) Change in NWC as a % of change in revenue held constant from 2027E   (3) Liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 67.5% cash / 32.5% PIK split) based on management assumptions  (2)  (1)  (1)  Highly preliminary & confidential – Illustrative Analyses for Discussion  (3)  (2)  (1)  (1) 
 

 Discounted Cash Flow Analysis – Management Finance Case (Cont’d)  Enterprise Value Sensitivity – Combined  Implied Share Price Sensitivity  Enterprise Value Sensitivity – Core  Enterprise Value Sensitivity – New Products  ($ in millions)  Sources: Company financials  Notes: Assumes valuation date as of 09/30/2022; assumes tax rate of 21.0%; fiscal year ends Dec. 31  Highly preliminary & confidential – Illustrative Analyses for Discussion 
 

 Legal Disclaimer  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) is subject to a non-disclosure agreement and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service.  The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors.   Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction.  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”), is subject to a non-disclosure agreement between you and the Company and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. 
 


Exhibit (c)(6)

 Discussion MaterialsProject OptimusPrime  November 4, 2022 
 

 New vs. Previous Management Finance Case Comparison  ($ in millions)  Source: Company financials 
 

 Market Check Overview  PWP contacted 45 parties   19 strategics  26 sponsors   Parties informed of agreement to pursue a go-private transaction with Paine Schwartz at $3.00 per share   Calls were made and 8-K and 13D were sent along with a note that the transaction is still subject to the execution of a definitive agreement  PWP offered to discuss if contacted parties were interested in learning more  Five parties are currently reviewing the opportunity internally  PWP’s Approach 
 

 Legal Disclaimer  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) is subject to a non-disclosure agreement and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service.  The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors.   Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction.  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”), is subject to a non-disclosure agreement between you and the Company and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. 
 


Exhibit (c)(7)

 Project Optimus PrimePresentation to the Special Committee  November 21, 2022 
 

 Optimus Prime Historical and Forecasted Financial Overview (Management Case)  Source: Company filings, historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee)  Note: (1) Excludes acquisitions  ($ in millions, all years reflect CY year-end 12/31)  (1) 
 

 Unaffected Ratings History  Price Target by Broker(1)  Equity Analyst View of Optimus Prime Stock  Select Broker Commentary  Source: Wall Street research, Capital IQ as of 11/18/2022  Note: (1) HC Wainwright placed Optimus Prime stock under review due to proposed buyout and did not offer a price target or rating in most recent report dated 11/10/2022  Roth Capital Partners   11/10/2022  Lake Street Capital Markets   11/10/2022  BMO Capital Markets  11/10/2022  Buy  Hold  “[Company] offers among the broadest product offerings in the food waste category and believe double-digit growth from its next-generation products seen since 2021 can continue to deliver alpha from current levels.” – Lake Street Capital Markets (11/10/2022)  “… the increase in revenue was approximately 3.1% YoY. We believe revenue growth was supported by results from diversification efforts.” – HC Wainwright (11/10/2022)  “[Company] continues to execute on its diversification strategy posting the seventh consecutive quarter of growth.” – Roth Capital Partners (11/10/2022)  “We slightly lower estimates following a disappointing Q3 update largely owing to FX … [Company] earnings remain somewhat flattish with a slight trajectory upward.” – BMO Capital Markets (11/10/2022) 
 

 Last 12 Months Share Price and Trading Volume  Since De-spac (08/03/2015)  Optimus Prime Stock Price Performance  Source: Capital IQ as of 11/18/2022  Notes: High Value Specialties includes Croda, Chr Hansen, Balchem and Novozymes; Large AgChem includes Nutrien, Mosaic, FMC Corp, CF Industries, Dow, Bayer, Corteva, BASF, Nufarm and UPL Limited; AgChem / AgTech includes FMC Corp, Scotts Miracle-Gro, Bioceres and American Vanguard; Food Safety / Security includes Ecolab, Sotera, Diversey and Neogen  Offer Price: $3.00  Offer Price: $3.00  06/15/20: Announces $150M convertible preferred equity investment from Paine Schwartz Partners  10/27/2022: Announces the Special Committee of Optimus Prime agreed with Paine Schwartz Partners to pursue a transaction in which Paine Schwartz Partners would acquire all outstanding common stock for $3.00 per share  10/27/2022: Trading volume peaked at 39M+ shares (not shown to scale); next highest volume during LTM occurred on 10/28/2022 at ~2.1M shares  Unaffected (10/26/2022) Optimus Prime VWAPs  30-Day  $1.58  60-Day  $1.60  90-Day  $1.68 
 

 Unaffected EV and Valuation  EV / NTM EBITDA Over Time (Since January 2019)(6)(7)  Optimus Prime Public Market Trading Multiple Over Time  Share Price (10/26/2022)(1)  $1.57   (x) Fully Diluted Shares(2)  58.460  Equity Value  $91.8   (-) Cash(3)  (35.6)   (+) Debt(4)  261.3   (+) Preferred at Liquidation Preference(5)  253.7   (+) Non-Controlling Interest(3)  6.9  Enterprise Value  $578.1  Management Case Multiples  CY2022E  CY2023E   EV / Revenue  3.5x  3.2x   EV / EBITDA  9.6x  9.1x  Consensus Multiples  CY2022E  CY2023E   EV / Revenue  3.5x  3.2x   EV / EBITDA  9.9x  9.1x  Source: Company filings, Historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee), FactSet and Capital IQ as of 11/18/2022  Notes: (1) Unaffected stock price prior to the announcement of Paine Schwartz Partners’ take-private of Optimus Prime   (2) Calculated as basic shares outstanding plus the effects of dilutive securities provided by the Company on 11/18/2022   (3) As of Q3 2022   (4) Includes principal value of Term Loan B ($260.438M) and Optimus Prime Fruit Protection Loan ($0.897M) per Q3 2022 10-Q   (5) Reflects change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions   (6) Earliest publication of 3rd party EV/NTM EBITDA data after De-SPAC on 08/03/2015   (7) Convertible preferred equity not reflected in EV / NTM EBITDA over time for Optimus Prime  06/15/2020: Announces $150M convertible preferred equity investment from   Paine Schwartz Partners  10/27/2022: Announces the Special Committee of Optimus Prime agreed with Paine Schwartz Partners to pursue a transaction in which Paine Schwartz Partners would acquire all outstanding common stock for $3.00 per share  Offer EV and Valuation  Offer Price  $3.00   (x) Fully Diluted Shares(2)  58.460  Offer Value  $175.4   (-) Cash(3)  (35.6)   (+) Debt(4)  261.3   (+) Preferred at Liquidation Preference(5)  253.7   (+) Non-Controlling Interest(3)  6.9  Enterprise Value  $661.7  Management Case Multiples  CY2022E  CY2023E   EV / Revenue  4.0x  3.7x   EV / EBITDA  11.0x  10.4x  Consensus Multiples  CY2022E  CY2023E   EV / Revenue  4.0x  3.7x   EV / EBITDA  11.3x  10.4x  ($ in millions, except share price) 
 

 Valuation Summary  Unaffected (10/26)  Price: $1.57  Source: Company filings, historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee)  Notes: Unaffected share price as of 10/26/2022   Enterprise value-based valuation methodologies reflect change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions   (1) Broker price targets represent 12-month targets; prices discounted 12 months from date of publication to 10/26/2022; reflects latest unaffected price targets; assumes cost of equity of 19.0%   (2) Based on unaffected current median of AgChem / AgTech and unaffected Optimus Prime 2023E trading multiple   (3) Based on +/- 1.0x vs. median of precedent transactions   (4) Core Products WACC range derived using cost of equity implied by CAPM at optimal capital structure (~13.0% WACC) and cost of equity implied by the yield on Paine Schwartz Partners' preferred equity investment in Optimus Prime assuming redemption on 07/27/2023 at current capital structure (~15.5% WACC)   (5) New Products WACC assumed to be 200 bps greater than Core Products WACC to reflect greater execution risk; assumes full achievability of New Products  (1)  Offer   Price: $3.00  (2)  (4)  (5)  (4)  (5)  (3) 
 

 EV / CY2023E EBITDA  EV / CY2022E EBITDA  Current Public Market Valuations of Selected Peers  Source: Company filings, historical financials and management forecasts provided by the Company on 11/01/2022 (approved for our use by the Special Committee), FactSet and Capital IQ as of 11/18/2022  Notes: (1) Reflects change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions  Optimus Prime  (Offer)(1)  Optimus Prime  (Unaffected) (1)  Optimus Prime  (Offer) (1)  Optimus Prime  (Unaffected) (1)   AgChem / AgTech   High Value Specialties   Food Safety / Security 
 

 Date  12/21/2021  12/14/2021  6/28/2021  3/24/2021  10/19/2020  10/12/2020  7/17/2020  9/30/2019  7/20/2018  4/30/2015  9/11/2014  Acquirer  Target  Enterprise Value ($M)  $198  $5,300  $170  $402  $165  $1,500  $1,142  $1,188  $4,200  $879  $2,773  EV / EBITDA for Select Precedent Transactions  Select Precedent Transactions  Source: Company filings, Moody’s, press releases  (Food Safety Business)  (South American Plan Nutrition Business)  Mean: 11.4x  Median: 10.2x 
 

 Discounted Cash Flow Analysis – Management Case  New Products Unlevered Free Cash Flows  Core Products Unlevered Free Cash Flows  Combined Terminal Value Build and Valuation  Sources: Company filings, historical financials and management forecasts provided by the Company on 11/10/2022 (approved for our use by the Special Committee), FactSet as of 11/18/2022  Notes: Assumes valuation date of 11/18/2022; assumes tax rate of 25.0%; fiscal year ends Dec. 31; WACCs of 14.25% and 16.25% utilized for Core Products and New Products respectively; perpetuity growth rates of 1.0% and 3.0% utilized for Core Products and New Products, respectively; D&A, SBC, and change in NWC allocated based on in-year sales contribution; CapEx allocated based on forward year sales contribution (excl. 2032E); assumes full achievability of New Products   (1) 2022E-2026E amortization sourced from Q3 2022 10-Q estimated annual amortization schedule; 2027E-2032E amortization assumed to decrease by (0.5%) each year   (2) Change in NWC as a % of change in revenue held constant from 2027E   (3) As of Q3 2022   (4) Includes principal value of Term Loan B ($260.438M) and Optimus Prime Fruit Protection Loan ($0.897M) per Q3 2022 10-Q   (5) Reflects change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023; liquidation preference assumes 50% cash / 50% PIK split for future preferred stock dividends (vs. option to elect 62.5% cash / 37.5% PIK split) based on management assumptions   (6) Calculated as basic shares outstanding plus the effects of dilutive securities provided by the Company on 11/18/2022  (5)  (2)  (1)  (1)  (2)  (1)  (1)  (4)  (3)  (3)  (6)  ($ in millions, except share price) 
 

 Discounted Cash Flow Sensitivities – Management Case  Enterprise Value Sensitivity – Combined(1)(2)  Implied Share Price Sensitivity(1)(2)  Enterprise Value Sensitivity – Core Products(1)  Enterprise Value Sensitivity – New Products(2)  Sources: Historical financials and management forecasts provided by the Company on 11/10/2022 (approved for our use by the Special Committee)  Notes: Assumes valuation date of 11/18/2022; assumes tax rate of 25.0%; fiscal year ends Dec. 31; assumes full achievability of New Products   (1) Core Products WACC range derived using cost of equity implied by CAPM at optimal capital structure (~13.0% WACC) and cost of equity implied by the yield on Paine Schwartz Partners' preferred equity investment in Optimus Prime assuming redemption on 07/27/2023 at current capital structure (~15.5% WACC)   (2) New Products WACC assumed to be 200 bps greater than Core Products WACC to reflect greater execution risk  ($ in millions, except share price) 
 

 Precedent Premia Analysis  Source: FactSet as of 11/18/2022  Notes: Unaffected premiums shown for acquisitions since 11/18/2020 with a transaction value between $100M – $3B and targets in the United States; excludes MOEs and transactions with targets industries of Energy, Insurance, Mining, Oil & Gas, REITs, Railroads, and Utilities 
 

 Appendix  12 
 

 CAPM approach – Bloomberg 5Y Weekly Beta at Optimal Capital Structure  Cost of Equity Floor at Yield on Convertible Preferred Equity At Current Capital Structure  Illustrative WACC Analysis – CAPM vs. Yield of Preferred Equity  Source: Company filings, Bloomberg, Kroll, Mizuho, FactSet and Capital IQ as of 11/18/2022  Notes: (1) 5-year weekly Bloomberg Beta; Optimus Prime beta as of unaffected date (10/26/2022); all peer betas as of 11/18/2022   (2) Deloitte Corporate Tax Rates 2022   (3) Includes principal value of Term Loan B ($260.438M) and Optimus Prime Fruit Protection Loan ($0.897M)   (4) Equity calculated as of 10/26/2022 using basic shares outstanding plus the effects of dilutive securities as of 11/18/2022; includes value of convertible preferred equity, reflecting change of control for Paine Schwartz Partners' convertible preferred equity at 2.0x MOIC assuming redemption date of 01/31/2023   (5) Kroll’s supply-side long term equity risk premium   (6) 20-year treasury rate as of 10/26/2022   (7) Size premium interpolated based on Kroll size premia by market cap range using assumed optimal capital structure for Optimus Prime of 80% Equity / Capitalization   (8) Based on effective yield for high-yield chemicals sector index   (9) Refers to yield on Paine Schwartz Partners' preferred equity investment in Optimus Prime, ranging from 16% total annual coupon yield on to ~27% IRR on investment assuming redemption on 07/27/2023  ($ in millions) 
 

 Legal Disclaimer  This Presentation has been provided to you by Perella Weinberg Partners and its affiliates (collectively “Perella Weinberg Partners” or the “Firm”) and may not be used or relied upon for any purpose without the written consent of Perella Weinberg Partners. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree that you and your directors, partners, officers, employees, attorney(s), agents and representatives agree to use it for informational purposes only and will not divulge any such Information to any other party. Reproduction of this Information, in whole or in part, is prohibited. These contents are proprietary and a product of Perella Weinberg Partners. The Information contained herein is not an offer to buy or sell or a solicitation of an offer to buy or sell any corporate advisory services or security or to participate in any corporate advisory services or trading strategy. Any decision regarding corporate advisory services or to invest in the investments described herein should be made after, as applicable, reviewing such definitive offering memorandum, conducting such investigations as you deem necessary and consulting the investor’s own investment, legal, accounting and tax advisors in order to make an independent determination of the suitability and consequences of an investment or service.  The information used in preparing these materials may have been obtained from or through you or your representatives or from public sources. Perella Weinberg Partners assumes no responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. To the extent such information includes estimates and/or forecasts of future financial performance (including estimates of potential cost savings and synergies) prepared by or reviewed or discussed with the managements of your company and/or other potential transaction participants or obtained from public sources, we have assumed that such estimates and forecasts have been reasonably prepared on bases reflecting the best currently available estimates and judgments of such managements (or, with respect to estimates and forecasts obtained from public sources, represent reasonable estimates). The Firm has no obligation (express or implied) to update any or all of the Information or to advise you of any changes; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors.   Nothing contained herein should be construed as tax, accounting or legal advice. You (and each of your employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by these materials and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and structure. For this purpose, the tax treatment of a transaction is the purported or claimed U.S. federal income tax treatment of the transaction and the tax structure of a transaction is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of the transaction. 
 


Exhibit (d)(4)

Paine Schwartz Food Chain Fund VI, L.P.
475 Fifth Street, 17th Floor
New York, NY 10017
 
November 21, 2022

Project Cloud Holdings, LLC
c/o Paine Schwartz Partners, LLC
475 Fifth Street, 17th Floor
New York, NY 10017

Re:          Equity Financing Commitment
 
Ladies and Gentlemen:
 
This letter agreement (this “Agreement”) sets forth the commitment of Paine Schwartz Food Chain Fund VI, L.P., a Cayman Islands limited partnership (the “Investor”), subject to the terms and conditions hereof, to purchase, or cause an assignee permitted by paragraph 3 of this Agreement to purchase, directly or indirectly, equity securities of Project Cloud Holdings, LLC, a Delaware limited liability company (“Parent”), at or immediately prior to the Closing.  It is contemplated that pursuant to the Agreement and Plan of Merger (as it may be amended, supplemented or modified from time to time, the “Merger Agreement”), dated as of the date hereof, by and among Parent, Project Cloud Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”) and AgroFresh Solutions, Inc., a Delaware corporation (the “Company”), Parent shall acquire the Company through the merger of Merger Sub with and into the Company.  Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to them in the Merger Agreement.
 
1.
 

(a)
Upon the terms and subject to the conditions set forth herein, the Investor hereby commits to (x) purchase, or cause an assignee or assignees permitted by paragraph 3 of this Agreement to purchase, in cash, directly or indirectly, at or immediately prior to the Closing, $200,000,000 of equity securities of Parent plus, to the extent necessary, an additional amount of equity securities of Parent for the payments contemplated by sub-clause (iii) below, solely for the purpose of allowing Parent and/or Merger Sub to fund any and all amounts required to be paid by Parent in connection with the Merger Agreement at the Closing, including (i) the aggregate cash consideration to which the holders of Shares and Series A Shares become entitled, respectively, pursuant to Section 4.1 of the Merger Agreement, (ii) the aggregate cash consideration to which the holders of Company Stock Options, Company SARs, Company RSU Awards, Company Phantom RSU Awards, Company PSU Awards, Company Phantom PSU Awards and Company Restricted Shares become entitled, respectively, pursuant to Section 4.3 of the Merger Agreement, in the case of each of clause (i) and (ii), payable at Closing (clauses (i) and (ii), collectively, the “Merger Consideration”), and (iii) to pay any and all related fees and expenses, in each case required to be paid at the Closing in connection with the Merger Agreement (the commitment described in this clause (x), the “Closing Payment Commitment”) or (y) pay, or cause an assignee or assignees permitted by paragraph 3 of this Agreement to pay, in cash, (i) (A) $43,000,000 for the payment of monetary damages to the Company in the event of an issuance, following the termination of the Merger Agreement, of a Final Order (as defined below) that requires Parent and/or Merger Sub to pay damages to the Company for any Fraud or in respect of a Willful and Material Breach of the terms of the Merger Agreement plus (B) any Enforcement Costs (the “Damages Commitment”), plus (ii) to the extent applicable, any Parent Reimbursement Obligations (the “Reimbursement Commitment” and together with the Damages Commitment, collectively, the “Termination Commitment” and the preceding clauses (x) or (y), as the case may be, the “Commitment”).  Subject to the conditions set forth in paragraph 2 below, the Investor will fund, or cause to be funded, the Closing Payment Commitment in cash at or immediately prior to the Closing on the Closing Date in connection with the substantially simultaneous issuance to the Investor of the equity of Parent or an affiliated parent entity of Parent.
 

November 21, 2022
Page 2


(b)
Subject to the terms and conditions hereof,  Parent hereby agrees to issue and sell equity and/or debt securities of Parent for an aggregate purchase price in cash of up to the Commitment for the purposes stated in paragraph 1(a); provided, that any purchase of debt securities shall not in any way affect the Closing (including where Parent obtains debt financing in connection with the Merger), or the accuracy of the Investor’s representations and warranties set forth in paragraph 8 of this Agreement.  The proceeds from the Investor’s investment shall be used solely for funding any and all amounts due and payable up to the Commitment pursuant to either clause (x) or (y) of paragraph 1(a), and the Investor shall not, under any circumstances, be obligated to contribute to Parent more than the Commitment. The obligations of the Investor to fund any portion of the Commitment may be reduced by the Investor on a dollar-for-dollar basis by any amounts actually contributed, directly or indirectly, to Parent to fund, or cause to be funded, the Commitment; provided, for the avoidance of doubt, that the Investor shall retain all liability to fund any portion of the Closing Payment Commitment that is not funded to Parent to consummate the Merger; provided further that, in each case, any such reduction shall not occur unless and until (I) in the event that the Closing shall occur, simultaneously with the occurrence of the Closing, (II) in the event that the Closing shall not have occurred and the Merger Agreement shall have been terminated, such time as the Termination Commitment shall have been satisfied in full, it being understood that the Termination Commitment shall be deemed satisfied in full in the event a Final Order is issued providing for damages of less than the Parent Liability Limitation and Parent has paid or caused to be paid such lesser amount plus any Enforcement Costs and Parent Reimbursement Obligations in accordance with the terms of this Agreement.  “Final Order” means a final, binding and non-appealable order of a court of competent jurisdiction in accordance with Section 9.5(a) of the Merger Agreement.
 
2.            The Investor’s obligations under this Agreement, including the obligation of the Investor to fund the Commitment, are subject to: (a) the execution and delivery of the Merger Agreement, (b) in respect of the Closing Payment Commitment only, the satisfaction or written waiver by the parties to the Merger Agreement, as applicable, of each of the conditions to such parties’ obligations to consummate the transactions contemplated by the Merger Agreement (other than any conditions that by their nature are to be satisfied at the Closing, but subject to the prior or substantially concurrent satisfaction of such conditions), and the substantially concurrent consummation of the Merger in accordance with the terms of the Merger Agreement, (c) in the case of the Reimbursement Commitment, the termination of the Agreement and (d) in the case of the Damages Commitment, the termination of the Merger Agreement and a Final Order having been issued requiring Parent to pay damages to the Company in respect of Fraud or a Willful and Material Breach of the Merger Agreement prior to the date of such termination. For the avoidance of doubt, the obligations of Parent under the Merger Agreement shall be determined in accordance with the terms thereof, and nothing in this Agreement shall amend, modify, or waive any of the terms of the Merger Agreement or any defenses that Parent may have to any assertion of liability or obligation against it under the Merger Agreement.
 
2

November 21, 2022
Page 3

3.           This Agreement and the obligation of the Investor to fund the Commitment, or cause the Commitment to be funded, shall automatically and immediately terminate upon the earlier to occur of (a) the consummation of the Closing and the payment of all amounts required to be paid at Closing, including the payment of the Merger Consideration in accordance with the Merger Agreement (at which time the obligation shall be discharged), (b) the valid termination of the Merger Agreement in accordance with its terms; provided, however, that, the Investor’s obligation to pay or cause to be paid any portion of the Termination Commitment shall survive any such termination and remain in full force and effect and shall be enforceable by each of Parent and, pursuant to and subject to the limitations set forth in paragraph 6, the Company, to the extent necessary to require the Investor to provide funds to Parent pursuant to clause (y) of paragraph 1(a), for a period of six (6) months following the termination of the Merger Agreement in accordance with its terms (the “Final Termination Date”), unless prior to the end of such period the Company shall have commenced a legal proceeding in a Chosen Court alleging amounts payable by Parent and/or Merger Sub to the Company in respect of Fraud or a Willful and Material Breach of the Merger Agreement, in which case the Final Termination Date shall be automatically extended until the day immediately following the earlier to occur of (x) a Final Order resolving such legal proceeding and satisfaction of the Termination Commitment, if applicable, or (y) a written agreement signed by each of the parties hereto terminating the Termination Commitment and (c) the Company or any of its Affiliates, Subsidiaries, officers or Directors (other than Recused Directors) filing, any claim or action against Parent, Merger Sub, the Investor or any of their respective Affiliates (including the Investor Affiliates (as defined below)), or, on behalf or at the request of the Company, any of the Company’s advisors or representatives, in connection with the transactions contemplated by the Merger Agreement, in each case other than (A) claims and/or actions by the Company against the Investor under this Agreement (to the extent expressly permitted under paragraph 6 of this Agreement), (B) claims and/or actions by the Company against Parent and/or Merger Sub under the Merger Agreement (but solely to the extent permitted thereby), and (C) claims and/or actions by the Company under the Support Agreement.  Paragraphs 3, 4, 5, 6, 7 and 10 shall remain in full force and effect, notwithstanding any termination of this Agreement.  The Commitment set forth herein shall not be assignable by Parent without the Investor’s and the Company’s prior written consent, and the granting of such consent in a given instance shall be solely in the discretion of each of the Investor and the Company and, if granted, shall not constitute a waiver of this requirement as to any subsequent assignment.  The rights of the Company hereunder shall not be assignable by the Company without the Investor's and Parent's prior written consent, and the granting of such consent in a given instance shall be solely in the discretion of the Investor and Parent and, if granted, shall not constitute a waiver of this requirement as to any subsequent assignment.  The obligations of the Investor hereunder shall not be assignable by the Investor without Parent’s and the Company’s prior written consent, and the granting of such consent in a given instance shall be solely in the discretion of each of Parent and the Company and, if granted, shall not constitute a waiver of this requirement as to any subsequent assignment; provided that, subject to paragraph 1(b), the Investor may assign one or more portions of its Commitment to any of its Affiliates and/or to any fund or entity advised by Investor or its Affiliates so long as such assignment does not impair, delay or prevent the consummation of the Closing; provided, further, that no such assignment by the Investor shall relieve the Investor of any of its obligations hereunder.  Any transfer or assignment in violation of the preceding three sentences shall be null and void.  This Agreement and the Merger Agreement set forth the entire agreement of the parties with respect to the subject matter hereof and supersede all prior arrangements and understandings with respect thereto.
 
3

November 21, 2022
Page 4

4.           Other than as required by applicable Law or the rules of any national securities exchange (including as and to the extent required in connection with any SEC filing relating to the Merger and the other transactions contemplated by the Merger Agreement) (each a “Relevant Authority”) or in connection with the enforcement of, or any Action related to or arising in connection with, this Agreement or the Merger Agreement, each of the parties agree that it will not, nor will it permit its representatives, advisors or Affiliates to, disclose to any Person the contents of this Agreement, other than to (a) their respective Affiliates, limited partners, general partners, members, managers, directors, officers, employees, agents and advisors (collectively, “Representatives”) and (b) the Company and its Representatives; provided, that each of the foregoing is instructed to maintain the confidentiality of this Agreement subject to the terms set forth herein. Notwithstanding the preceding sentence, the Company, the Investor, and their respective Affiliates and Representatives shall have the right to make such disclosures as are required by any Governmental Authority having jurisdiction over the Company, the Investor, and their respective Affiliates or Representatives; provided that, except to the extent not reasonably practicable or as may be prohibited by applicable Law, such disclosing party shall provide a copy of any such disclosure to the other parties hereto, with a reasonable opportunity promptly to review and provide written comment on any such disclosure in advance, and the disclosing party shall consider such written comments in good faith.
 
5.           The Investor Affiliates are express third party beneficiaries of paragraphs 3, 4, 5, 6, 7, 9, 10 and 11 of this Agreement. Notwithstanding anything that may be expressed or implied in this Agreement or any document or instrument delivered in connection herewith, each party hereto, by its acceptance of the benefits hereof, covenants, agrees and acknowledges that no Person other than Parent and the Investor has obligations hereunder and that, notwithstanding that the Investor is a limited partnership, no Person has any remedy, recourse or right of recovery hereunder against, or contribution from any Investor Affiliate, through the Investor, Parent, Merger Sub or otherwise, whether by or through attempted piercing of the corporate (or limited liability company or partnership) veil or similar action, by the enforcement of any assessment or by any legal or equitable proceeding, by virtue of any statute, regulation or applicable law, by or through a claim by or on behalf of the Investor, Parent or Merger Sub against the Investor or any Investor Affiliate, or otherwise.  For purposes of this Agreement, the term “Investor Affiliate” means any former, current or future general or limited partners, stockholders, holders of any equity, partnership or limited liability company interest, officer, member, manager, director, employees, agents, controlling persons, assignee or Affiliates of the Investor or the foregoing (it being understood that the term Investor Affiliate shall not include the Investor, Parent or Merger Sub).  For the avoidance of doubt, neither the Investor nor any Investor Affiliate is a party to, or has any obligations under, the Merger Agreement.
 
6.            Except as otherwise set forth in paragraph 5 or this paragraph 6, this Agreement is solely for the benefit of Parent and is not intended to, nor does it, confer any benefits on, or create any rights or remedies in favor of, any person other than Parent. In no event shall any of Parent’s creditors have any right to enforce this Agreement or to cause Parent to enforce this Agreement. Notwithstanding anything that may be expressed or implied in this Agreement to the contrary, the Company (but, for the avoidance of doubt, not its stockholders or any of its other securityholders) is hereby made an express and intended third-party beneficiary of this Agreement and may enforce the terms of this Agreement against the Investor and Parent as if the Company were a party hereto (a) solely with respect to the Closing Payment Commitment, if, and only if, (i) all conditions set forth in Section 7.1 and Section 7.2 of the Merger Agreement have been satisfied or waived (other than those conditions that, by their terms, cannot be satisfied until the Closing but which are fully capable of being satisfied at the Closing) and (ii) Parent and Merger Sub fail to consummate the Closing by the date on which the Closing would otherwise be required to have occurred pursuant to Section 1.2 of the Merger Agreement, (b) solely with respect to the Damages Commitment, solely pursuant to a Final Order and subject to the limitations (including the cap on damages) set forth in this Agreement and the Merger Agreement, (c) solely with respect to the Reimbursement Commitment, solely following a termination of the Merger Agreement, and (d) to enforce the provisions of paragraphs 9, 10, 11 and 12 of this Agreement, and in each of the cases of clauses “(a)”, “(b)” “(c)” and (d) above, without a requirement to post a bond or other security as a prerequisite to obtaining equitable relief .
 
7.           Each party acknowledges and agrees that (a) this Agreement is not intended to, and does not, create any agency, partnership, fiduciary or joint venture relationship between or among any of the parties hereto and neither this Agreement nor any other document or agreement entered into by any party hereto relating to the subject matter hereof shall be construed to suggest otherwise and (b) the obligations of the Investor under this Agreement are solely contractual and not fiduciary in nature.
 
4

November 21, 2022
Page 5

8.           The Investor hereby represents and warrants with respect to itself to Parent that (a) it has all limited partnership power and authority to execute, deliver and perform this Agreement; (b) the execution, delivery and performance of this Agreement by the Investor has been duly and validly authorized and approved by all necessary limited partnership action by it; (c) this Agreement has been duly and validly executed and delivered by it and, assuming due and valid authorization, execution and delivery by the other parties hereto, constitutes a valid and legally binding obligation of it, enforceable against it in accordance with the terms of this Agreement; (d) it has and will have for so long as this Agreement shall remain in effect uncalled capital commitments or otherwise will have available funds sufficient to fund the amount of (i) the Closing Payment Commitment when and as required hereunder for so long as the Merger Agreement has not been terminated or (ii) the Damages Commitment when and as required hereunder for so long as this Agreement shall remain in effect in accordance with paragraph 3 hereof; (e) except for such consents, approvals, authorizations, permits of, filings with and notifications to, Governmental Authorities contemplated by the Merger Agreement to be obtained or made after the date hereof, all consents, approvals, authorizations, permits of, filings with and notifications to, any Governmental Authority necessary for the due execution, delivery and performance of this Agreement by the Investor have been obtained or made and all conditions thereof have been duly complied with, and no other action by, and no notice to or filing with, any Governmental Authority is required in connection with the execution, delivery or performance of this Agreement; (f) there is not in existence any document, agreement, arrangement or understanding in relation to any aspect of this Agreement to which the Investor, Parent, or any of their Affiliates is a party which would prejudice Parent’s ability to pay or procure payment of the amounts payable pursuant to the Merger Agreement or the Investor’s ability to fund the Commitment pursuant to this Agreement; and (g)(i) it and its Affiliates and their representatives will not cause Parent to file for any voluntary Insolvency Proceeding, (ii) the Investor will take all necessary actions so that Parent does not file for any voluntary Insolvency Proceeding and (iii) the Investor will use reasonable best efforts to oppose any involuntary Insolvency Proceeding, in each case with respect to Parent (for the avoidance of doubt, in no event shall such efforts include the obligation to provide or expend funds that are not otherwise required to be provided or expended pursuant to this Agreement).  “Insolvency Proceeding” means any insolvency, bankruptcy, winding up, moratorium, receivership, dissolution, assignment, reorganization or other similar proceeding under any provisions of federal or state bankruptcy Law.
 
9.            This Agreement may not be amended or otherwise modified without the prior written consent of Parent, the Investor and the Company.
 
10.
 

(a)
THIS AGREEMENT AND ANY CLAIM, CAUSE OF ACTION OR ACTION (WHETHER AT LAW, IN CONTRACT OR IN TORT) THAT MAY DIRECTLY OR INDIRECTLY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS AGREEMENT OR ANY TRANSACTION CONTEMPATED HEREBY, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO ANY CHOICE OR CONFLICTS OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF DELAWARE.  Each of the parties hereto (i) expressly submits to the personal jurisdiction and venue of the Chosen Courts in the event any dispute between the parties hereto (whether in contract, tort or otherwise) arises out of this Agreement or the transactions contemplated hereby, (ii) expressly waives any claim of lack of personal jurisdiction or improper venue and any claims that such courts are an inconvenient forum with respect to such a claim, and (iii) agrees that it shall not bring any claim, action or proceeding against any other parties hereto relating to this Agreement or the transactions contemplated hereby in any court other than the Chosen Courts.  Each party hereto hereby irrevocably consents to the service of process of any of the aforementioned courts in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail or by overnight courier service, postage prepaid, to its address set forth herein or in Section 9.6 of the Merger Agreement, as applicable, with such service to become effective ten (10) days after such mailing.
 
5

November 21, 2022
Page 6


(b)
EACH PARTY HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION, DIRECTLY OR INDIRECTLY, ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.  EACH PARTY (i) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (II) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS PARAGRAPH 10(b).
 
11.          This Agreement may be executed (including by an electronic signature (e.g., DocuSign)) in any number of counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by email of a .pdf attachment shall be effective as delivery of a manually executed counterpart of this Agreement.
 
12.          For all purposes hereunder, the Company (prior to the Effective Time) and the Company Board, as applicable, shall act, including with respect to the granting of any consent, permission or waiver or the making of any determination, only as directed by the Special Committee or its designees.
 
* * * * * * *
 
6

If this Agreement is agreeable to you, please so indicate by signing in the space indicated below.
 
 
Very truly yours,
   
 
PAINE SCHWARTZ FOOD CHAIN FUND VI, L.P.
     
 
By:
Paine Schwartz Food Chain Fund VI GP, L.P.
 
Its:
General Partner
     
 
By:
Paine Schwartz Food Chain Fund VI UGP, LLC
 
Its:
General Partner

 
By:
/s/ Kevin Schwartz
 
Name:
Kevin Schwartz
 
Title:
Managing Member

Accepted and agreed as of the date first written above
 
   
PROJECT CLOUD HOLDINGS, LLC
 
     
By:
/s/ Kevin Schwartz  
Name:
Kevin Schwartz  
Title:
President and Chief Executive Officer
 

Signature Page to Equity Commitment Letter




Exhibit 107

Calculation of Filing Fee Tables
 
Schedule 13E-3
(Form Type)

AgroFresh Solutions, Inc.
Project Cloud Merger Sub, Inc.
Project Cloud Holdings, LLC
Paine Schwartz Food Chain Fund V, L.P.
Paine Schwartz Food Chain Fund V GP, L.P.
Paine Schwartz Food Chain Fund V GP, Ltd.
Paine Schwartz Food Chain Fund VI, L.P.
PSP AGFS Holdings, L.P.
Paine Schwartz Partners, LLC
(Exact Name of Registrant and Name of Persons Filing Statement)

Table 1 - Transaction Valuation
 
 
 
Transaction Valuation
 
 
Fee Rate
 
 
Amount of Filing Fee
 
 
Fees to be Paid
 
$
185,089,422.00
 (1)
 
 
0.0001102
 
 
$
20,397.00
 (2)
 
Fees Previously Paid
 
$
0
 
 
 
 
 
 
 
20,397.00
 
 
Total Transaction Valuation
 
$
185,089,422.00
               
 
 
Total Fees Due for Filing
 
 
             
$
0
 
 
Total Fees Previously Paid
 
 
 
 
 
 
 
 
 
 
20,397.00
 
 
Total Fee Offsets
 
 
 
 
 
 
 
 
 
 
20,397.00
 (3)
 
Net Fee Due
 
 
 
 
 
 
 
 
 
$
0
 
 
 
Table 2 – Fee Offset Claims and Sources
 
 
 
Registrant
or Filer
Name
 
Form
or
Filing
Type
 
File
Number
 
Initial
Filing
Date
 
Filing
Date
 
 
Fee
Offset
Claimed
 
 
Fee Paid
with Fee
Offset Source
 
 
Fee Offset Claims
 
   
PREM 14A
 
001-36316
 
December 21, 2022
       
$20,397.00
     
 
 
Fee Offset Sources
 
AgroFresh Solutions, Inc.
 
PREM 14A
 
001-36316
     
December 21, 2022
         
$20,397.00
 
 
 
(1)
Aggregate number of securities to which transaction applies: As of November 11, 2022, the maximum number of securities of AgroFresh Solutions, Inc. (the “Company”) to which this transaction applies is estimated to be 61,696,474, which consists of (a) 53,052,352 shares of shares of the Company’s common stock, par value $0.0001 per share, entitled to receive the per share merger consideration of $3.00; (b) 1,554,909 shares of common stock underlying outstanding stock options, which are entitled to receive the per share merger consideration of $3.00 minus any applicable exercise price; (c) 41,250 shares of common stock underlying outstanding stock appreciation rights, which may be entitled to receive the per share merger consideration of $3.00 minus any applicable base price; (d) 2,026,646 shares of common stock underlying outstanding restricted stock units entitled to receive the per share merger consideration of $3.00; (e) 148,895 shares of common stock underlying outstanding phantom restricted stock units entitled to receive the per share merger consideration of $3.00; (f) a maximum of 4,048,320 shares of common stock underlying outstanding restricted stock units subject to performance-based vesting, which may be entitled to receive the per share merger consideration of $3.00 (assuming maximum achievement of all applicable performance conditions); (g) a maximum of 138,344 shares of common stock underlying outstanding phantom restricted stock units subject to performance-based vesting, which may be entitled to receive the per share merger consideration of $3.00 (assuming maximum achievement of all applicable performance conditions); (h) one share of Series A preferred stock, par value $0.0001 per share, entitled to receive the merger consideration of $3.00; and (i) 685,757 shares of common stock reserved for issuance pursuant to employee stock purchase plans.
   
(2)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Estimated solely for the purposes of calculating the filing fee, as of November 11, 2022, the underlying value of the transaction was calculated based on the sum (a) the product of 53,052,352 shares of common stock and the per share merger consideration of $3.00; (b) the product of 1,554,909 shares of common stock underlying outstanding stock options and the per share merger consideration of $3.00; (c) the product of 41,250 shares of common stock underlying outstanding stock appreciation rights and the per share merger consideration of $3.00; (d) the product of 2,026,646 shares of common stock underlying outstanding restricted stock units and the per share merger consideration of $3.00; (e) the product of 148,895 shares of common stock underlying outstanding phantom restricted stock units and the per share merger consideration of $3.00; (f) the product of 4,048,320 shares of common stock underlying outstanding restricted stock units subject to performance-based vesting and the per share merger consideration of $3.00 (assuming the restricted stock units vest at maximum achievement of all applicable performance conditions); (g) the product of 138,344 shares of common stock underlying outstanding phantom restricted stock units subject to performance-based vesting and the per share merger consideration of $3.00 (assuming the 138,344 shares are paid out at maximum achievement of all applicable performance conditions); (h) the product of the one share of Series A preferred stock and the merger consideration of $3.00; and (i) the product of 685,757 shares of common stock reserved for issuance pursuant to employee stock purchase plans and the per share merger consideration of $3.00. In accordance with Section 14(g) of the Securities Exchange Act of 1934, as amended, the filing fee was determined by multiplying the sum calculated in the preceding sentence by 0.0001102.
   
(3)
The Company previously paid $20,397.00 upon the filing of its Preliminary Proxy Statement on Schedule 14A on December 21, 2022 in connection with the transaction reported hereby.